Evolocumab vs Inclisiran

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline

Evolocumab · Repatha

Marketed by Amgen

Approved in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Partial signal

NCT01516879 · Phase 3 · completed

The study randomly assigned 905 participants to quadruple-blinded monthly evolocumab or placebo, with both groups continuing background lipid-lowering therapy. The primary endpoint was met, with a statistically significant difference in LDL-C change at week 52, but LDL-C is a surrogate laboratory endpoint rather than a clinical outcome.

Next expected readout: November 2026 · NCT06496243 (registry estimate)

Reported efficacy

Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08) (met)

Result source: NCT02392559

Inclisiran · Leqvio

Marketed by Novartis and partners

Phase 3 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
Partial signal

NCT03397121 · Phase 3 · completed

The trial randomly assigned 482 participants to double-blind inclisiran or placebo, with 242 receiving inclisiran and 240 receiving placebo. Both primary LDL-C comparisons were statistically significant in favor of inclisiran, but LDL-C is a surrogate laboratory endpoint rather than a hard clinical outcome, supporting a moderate evidence grade.

Next expected readout: November 2026 · NCT06501443 (registry estimate)

Reported efficacy

Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -27.14% (95% CI -32.04 to -22.24) vs Part 1 - Placebo 1.4% (95% CI -3.97 to 6.78) (met)

Result source: NCT04652726

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEvolocumabInclisiran
LDL-C, % change-50.1% vs 6.8%−57 vs placebowk 52 · n 599NCT01516879
57 other results
  • -44.5% vs -6.2% 420 mg QM · wk 24 · n 104 · Phase 3 · primary NCT02392559
  • -55.2% vs 1.7% wk 24 · n 295 · Phase 3 · primary NCT02833844
  • -61.6% vs 8.1% Q2W · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -58.2% vs 8.1% QM · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -61.8% vs 8.1% Q2W · wk 12 · n 109 · Phase 3 · primary NCT01763866
  • -58.7% vs 8.1% QM · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -60.1% vs 8.1% Q2W · wk 12 · n 113 · Phase 3 · primary NCT01763866
  • -59.4% vs 8.1% QM · wk 12 · n 115 · Phase 3 · primary NCT01763866
  • -58.9% vs 8.1% Q2W · wk 12 · n 111 · Phase 3 · primary NCT01763866
  • -52.4% vs 8.1% QM · wk 12 · n 112 · Phase 3 · primary NCT01763866
  • -65.9% vs 8.1% Q2W · wk 12 · n 112 · Phase 3 · primary NCT01763866
  • -57.0% vs 8.1% QM · wk 12 · n 115 · Phase 3 · primary NCT01763866
  • -57.0% vs -1.3% Q2W · wk 12 · n 153 · Phase 3 · primary NCT01763827
  • -56.1% vs -1.3% QM · wk 12 · n 153 · Phase 3 · primary NCT01763827
  • -62.3% vs 7.1% QM · wk 12 · n 332 · Phase 3 · primary NCT02662569
  • -54.3% vs -1.1% wk 12 · n 280 · Phase 3 · primary NCT02739984
  • -69.0% vs 4.9% QM · n 332 · Phase 3 · primary NCT02662569
  • -61.3% vs 5.5% Q2W · wk 12 · n 110 · Phase 3 · primary NCT01763918
  • -55.7% vs 5.5% QM · wk 12 · n 110 · Phase 3 · primary NCT01763918
  • -64.7% vs 7.1% Q2W · wk 12 · n 325 · Phase 3 · primary NCT02662569
  • -73.6% vs 1.4% Q2W · wk 12 · n 50 · Phase 3 · primary NCT01953328
  • -64.6% vs 1.4% QM · wk 12 · n 50 · Phase 3 · primary NCT01953328
  • -74.5% vs 1.4% Q2W · wk 12 · n 51 · Phase 3 · primary NCT01953328
  • -70.4% vs 1.4% QM · wk 12 · n 51 · Phase 3 · primary NCT01953328
  • -73.7% vs -0.4% Q2W · wk 11 · n 50 · Phase 3 · primary NCT01953328
  • -70.0% vs -0.4% QM · wk 11 · n 50 · Phase 3 · primary NCT01953328
  • -74.8% vs -0.4% Q2W · wk 11 · n 51 · Phase 3 · primary NCT01953328
  • -76.9% vs -0.4% QM · wk 11 · n 51 · Phase 3 · primary NCT01953328
  • -61.4% vs 7.5% Q2W · n 110 · Phase 3 · primary NCT01763866
  • -62.5% vs 7.5% QM · n 110 · Phase 3 · primary NCT01763866
  • -61.8% vs 7.5% Q2W · n 109 · Phase 3 · primary NCT01763866
  • -65.0% vs 7.5% QM · n 110 · Phase 3 · primary NCT01763866
  • -59.3% vs 7.5% Q2W · n 113 · Phase 3 · primary NCT01763866
  • -63.8% vs 7.5% QM · n 115 · Phase 3 · primary NCT01763866
  • -59.1% vs 7.5% Q2W · n 111 · Phase 3 · primary NCT01763866
  • -62.9% vs 7.5% QM · n 112 · Phase 3 · primary NCT01763866
  • -66.2% vs 7.5% Q2W · n 112 · Phase 3 · primary NCT01763866
  • -62.5% vs 7.5% QM · n 115 · Phase 3 · primary NCT01763866
  • -56.9% vs -1.4% Q2W · n 153 · Phase 3 · primary NCT01763827
  • -58.8% vs -1.4% QM · n 153 · Phase 3 · primary NCT01763827
  • -61.2% vs 2.3% Q2W · n 110 · Phase 3 · primary NCT01763918
  • -63.3% vs 2.3% QM · n 110 · Phase 3 · primary NCT01763918
  • -65.3% vs 4.9% Q2W · n 325 · Phase 3 · primary NCT02662569
  • -65.0% vs -0.8% n 280 · Phase 3 · primary NCT02739984
  • -23.1% vs 7.9% wk 12 · n 33 · Phase 2/3 · primary NCT01588496
  • -52.8% vs -16.7% wk 24 · n 145 · Phase 3 · primary NCT01984424
  • -56.1% vs -18.1% Q2W · wk 12 · n 103 · Phase 3 · primary NCT01763905
  • -52.6% vs -18.1% QM · wk 12 · n 102 · Phase 3 · primary NCT01763905
  • -54.5% vs -16.7% n 145 · Phase 3 · primary NCT01984424
  • -56.1% vs -19.2% Q2W · n 103 · Phase 3 · primary NCT01763905
  • -55.3% vs -19.2% QM · n 102 · Phase 3 · primary NCT01763905
  • -54.4% vs 3.2% wk 12 · n 599 · Phase 3 · secondary NCT01516879
  • -59.0% vs 1.6% 420 mg QM · wk 16 · n 62 · Phase 3 · secondary NCT02729025
  • -48.0% vs -5.9% 420 mg QM · n 104 · Phase 3 · secondary NCT02392559
  • -57.8% vs -0.7% wk 7.14 · n 18 · Phase 3 · secondary NCT02189837
  • -83.2% vs -0.7% wk 7.14 · n 17 · Phase 3 · secondary NCT02189837
  • -25.6% vs 4.2% n 33 · Phase 2/3 · secondary NCT01588496
-49.3% vs 4.2%−53.5 vs placebowk 72.9 · n 810NCT03400800
76 other results
  • -56.3% vs 1.3% wk 72.9 · n 781 · Phase 3 · primary NCT03399370
  • -45.8% vs 3.4% n 810 · Phase 3 · primary NCT03400800
  • -51.3% vs 2.5% n 781 · Phase 3 · primary NCT03399370
  • -41.1% vs 8.4% wk 73 · n 242 · Phase 3 · primary NCT03397121
  • -27.1% vs 1.4% wk 47.14 · n 93 · Phase 3 · primary NCT04652726
  • -45.9% vs 1.6% wk 21.43 · n 103 · Phase 3 · primary NCT05888103
  • -38.1% vs 6.2% n 242 · Phase 3 · primary NCT03397121
  • 0.7% vs 2.4% wk 21.43 · n 37 · Phase 3 · primary NCT03851705
  • -21.6% vs 11.7% wk 47.14 · n 9 · Phase 3 · primary NCT04659863
  • -45.6% vs 1.4% wk 47 · n 171 · Phase 3 · primary NCT04873934
  • -60% vs -7% wk 47 · n 205 · Phase 3 · primary NCT04929249
  • -26.1% vs 1.5% wk 51.43 · n 93 · Phase 3 · secondary NCT04652726
  • -26.0% vs 3.3% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -27.8% vs 1.5% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -19% vs 2.1% wk 38.57 · n 93 · Phase 3 · secondary NCT04652726
  • -7.2% vs -1.5% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -32.5% vs 6.4% wk 21.43 · n 93 · Phase 3 · secondary NCT04652726
  • 1.8% vs -2.9% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -23.9% vs -0.1% wk 12.86 · n 93 · Phase 3 · secondary NCT04652726
  • -8.7% vs 3.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -19.3% vs 5.4% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -21.6% vs 11.7% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -17.3% vs 10.2% wk 38.57 · n 9 · Phase 3 · secondary NCT04659863
  • -24.1% vs 17% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -26.1% vs 6.8% wk 12.86 · n 9 · Phase 3 · secondary NCT04659863
  • -44.3% vs 2.4% n 194 · Phase 3 · secondary NCT04873934
  • -57.2% vs -2.8% n 222 · Phase 3 · secondary NCT04929249
  • -56.3% vs 9% 300 mg · wk 25.714 · n 96 · Phase 2 · primary NCT04666298
  • -38.4% vs 2.1% 300 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -52.6% vs 2.1% 300 mg double dose · wk 25.71 · n 59 · Phase 2 · primary NCT02597127
  • -41.9% vs 2.1% 500 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -51.9% vs 9% 200 mg · wk 25.714 · n 101 · Phase 2 · primary NCT04666298
  • -27.9% vs 2.1% 200 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -44.9% vs 2.1% 200 mg double dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -47.6% vs 9% 100 mg · wk 25.714 · n 55 · Phase 2 · primary NCT04666298
  • -35.5% vs 2.1% 100 mg double dose · wk 25.71 · n 59 · Phase 2 · primary NCT02597127
  • -59.5% vs -24.3% wk 51.4 · n 898 · Phase 4 · secondary NCT05192941
  • -35.4% vs 1.4% 300 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -50.5% vs 1.4% 300 mg double dose · wk 30 · n 59 · Phase 2 · secondary NCT02597127
  • -66.2% vs 4.3% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -67.2% vs 2.3% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -43.3% vs -0.9% 300 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -54.7% vs -0.9% 300 mg double dose · wk 17.14 · n 59 · Phase 2 · secondary NCT02597127
  • -65.7% vs 1.2% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -61.5% vs 2.7% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -62.4% vs 0.2% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -50.9% vs -4.3% 300 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -51.0% vs -4.3% 300 mg double dose · wk 8.57 · n 59 · Phase 2 · secondary NCT02597127
  • -62.8% vs 1.3% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -47.6% vs 1.7% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -39.2% vs 1.4% 500 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -46.4% vs -0.9% 500 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -49.6% vs -4.3% 500 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -29.0% vs 1.4% 200 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -42.6% vs 1.4% 200 mg double dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -60.5% vs 4.3% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -62.0% vs 2.3% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -36.9% vs -0.9% 200 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -49.5% vs -0.9% 200 mg double dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -60.3% vs 1.2% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -53.9% vs 2.7% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -55.6% vs 0.2% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -44.3% vs -4.3% 200 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -44.3% vs -4.3% 200 mg double dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -55.5% vs 1.3% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -42.1% vs 1.7% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -31.7% vs 1.4% 100 mg double dose · wk 30 · n 59 · Phase 2 · secondary NCT02597127
  • -55.5% vs 4.3% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -54.9% vs 2.3% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -41.4% vs -0.9% 100 mg double dose · wk 17.14 · n 59 · Phase 2 · secondary NCT02597127
  • -53% vs 1.2% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -46.4% vs 2.7% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -50.1% vs 0.2% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -35.7% vs -4.3% 100 mg double dose · wk 8.57 · n 59 · Phase 2 · secondary NCT02597127
  • -52.2% vs 1.3% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -37.1% vs 1.7% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298
Non-HDL-C, % change-41.8% vs 8.4%−50.3 vs placebowk 52 · n 599NCT01516879
50 other results
  • -41.2% vs -6.1% 420 mg QM · wk 24 · n 104 · Phase 3 · secondary NCT02392559
  • -48.1% vs 2.9% wk 24 · n 296 · Phase 3 · secondary NCT02833844
  • -53.4% vs 7.9% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -52.2% vs 7.9% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -54.8% vs 7.9% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -50.0% vs 7.9% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -52.0% vs 7.9% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -51.6% vs 7.9% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -51.0% vs 7.9% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -46.4% vs 7.9% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -59.0% vs 7.9% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -51.0% vs 7.9% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -50.1% vs 1.5% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -49.7% vs 1.5% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -52.9% vs 5.9% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -59.1% vs 4.3% QM · n 332 · Phase 3 · secondary NCT02662569
  • -56.2% vs 5.3% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -49.7% vs 5.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -55.8% vs 5.9% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -46.9% vs -0.6% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -67.8% vs -0.1% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -58.0% vs -0.1% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -68.9% vs -0.1% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -63.3% vs -0.1% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -68.5% vs -1.6% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -61.7% vs -1.6% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -69.7% vs -1.6% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -69.1% vs -1.6% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -53.5% vs 7.0% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -56.1% vs 7.0% QM · n 110 · Phase 3 · secondary NCT01763866
  • -54.4% vs 7.0% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -56.3% vs 7.0% QM · n 110 · Phase 3 · secondary NCT01763866
  • -52.6% vs 7.0% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -55.5% vs 7.0% QM · n 115 · Phase 3 · secondary NCT01763866
  • -52.1% vs 7.0% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -55.7% vs 7.0% QM · n 112 · Phase 3 · secondary NCT01763866
  • -59.3% vs 7.0% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -56.0% vs 7.0% QM · n 115 · Phase 3 · secondary NCT01763866
  • -50.2% vs 1.3% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -52.0% vs 1.3% QM · n 153 · Phase 3 · secondary NCT01763827
  • -55.8% vs 2.7% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -57.3% vs 2.7% QM · n 110 · Phase 3 · secondary NCT01763918
  • -56.6% vs 4.3% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -56.6% vs -0.1% n 280 · Phase 3 · secondary NCT02739984
  • -45.7% vs -14.6% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -48.6% vs -16.5% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -46.1% vs -16.5% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -47.4% vs -14.4% n 145 · Phase 3 · secondary NCT01984424
  • -48.7% vs -17.2% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -49.1% vs -17.2% QM · n 102 · Phase 3 · secondary NCT01763905
-41.2% vs 2.1%−43.3 vs placebowk 72.9 · n 810NCT03400800
38 other results
  • -47.4% vs -0.1% wk 72.9 · n 781 · Phase 3 · secondary NCT03399370
  • -34.9% vs 7.4% wk 73 · n 242 · Phase 3 · secondary NCT03397121
  • -24% vs 1.2% wk 51.43 · n 92 · Phase 3 · secondary NCT04652726
  • -25.0% vs 1.8% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -25.7% vs 1.8% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -6.2% vs -1.1% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -29% vs 5.1% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -40.7% vs -0.1% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • 1.3% vs -1.7% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • 0.4% vs 2.5% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -7.2% vs 2.9% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -20.1% vs 7.1% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -23.3% vs 9.4% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -24% vs 19% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -54.0% vs 1.3% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -56.8% vs 2.0% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -58.7% vs 0.8% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -57.7% vs 2.0% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -53.2% vs 1.8% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -54.1% vs 0.6% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -54.2% vs 1.0% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -41.2% vs 1.1% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -50.1% vs 1.3% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -52.9% vs 2.0% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -53.5% vs 0.8% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -52.0% vs 2.0% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -47.2% vs 1.8% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -48.2% vs 0.6% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -48.0% vs 1.0% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -35.7% vs 1.1% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -44.8% vs 1.3% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -47.9% vs 2.0% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -48.2% vs 0.8% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -46.1% vs 2.0% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -39.8% vs 1.8% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -43.4% vs 0.6% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -44.7% vs 1.0% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -31.4% vs 1.1% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298
ApoB, % change-41.3% vs 2.9%−44.2 vs placebowk 52 · n 599NCT01516879
53 other results
  • -34.9% vs -2.4% 420 mg QM · wk 24 · n 104 · Phase 3 · secondary NCT02392559
  • -45.1% vs 2.6% wk 24 · n 302 · Phase 3 · secondary NCT02833844
  • -48.3% vs 3.3% 420 mg QM · wk 16 · n 63 · Phase 3 · secondary NCT02729025
  • -50.9% vs 6.3% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -47.1% vs 6.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -49.8% vs 6.3% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -46.5% vs 6.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -50.1% vs 6.3% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -48.6% vs 6.3% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -45.6% vs 6.3% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -43.7% vs 6.3% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -56.0% vs 6.3% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -49.2% vs 6.3% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -47.2% vs 1.8% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -46.6% vs 1.8% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -49.7% vs 3.2% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -56.4% vs 2.0% QM · n 332 · Phase 3 · secondary NCT02662569
  • -49.8% vs 4.6% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -44.8% vs 4.6% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -53.9% vs 3.2% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -40.3% vs 1.8% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -64.8% vs -2.5% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -54.8% vs -2.5% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -62.8% vs -2.5% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -64.4% vs -4.3% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -51.0% vs 5.1% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -51.4% vs 5.1% QM · n 110 · Phase 3 · secondary NCT01763866
  • -49.1% vs 5.1% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -53.3% vs 5.1% QM · n 110 · Phase 3 · secondary NCT01763866
  • -49.8% vs 5.1% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -53.6% vs 5.1% QM · n 115 · Phase 3 · secondary NCT01763866
  • -47.1% vs 5.1% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -53.0% vs 5.1% QM · n 112 · Phase 3 · secondary NCT01763866
  • -55.6% vs 5.1% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -54.4% vs 5.1% QM · n 115 · Phase 3 · secondary NCT01763866
  • -47.0% vs 1.5% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -49.4% vs 1.5% QM · n 153 · Phase 3 · secondary NCT01763827
  • -49.6% vs 2.2% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -52.8% vs 2.2% QM · n 110 · Phase 3 · secondary NCT01763918
  • -55.0% vs 2.0% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -50.2% vs 2.3% n 280 · Phase 3 · secondary NCT02739984
  • -19.2% vs 4.0% wk 12 · n 33 · Phase 2/3 · secondary NCT01588496
  • -58.0% vs -2.5% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -64.8% vs -4.3% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -58.5% vs -4.3% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -64.2% vs -4.3% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -20.2% vs 2.6% n 33 · Phase 2/3 · secondary NCT01588496
  • -43.5% vs -11.7% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -45.8% vs -12.9% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -43.1% vs -12.9% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -45.3% vs -11.4% n 145 · Phase 3 · secondary NCT01984424
  • -45.9% vs -13.7% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -46.0% vs -13.7% QM · n 102 · Phase 3 · secondary NCT01763905
-38.1% vs 0.8%−38.9 vs placebowk 72.9 · n 810NCT03400800
38 other results
  • -44.8% vs -1.7% wk 72.9 · n 781 · Phase 3 · secondary NCT03399370
  • -33.1% vs 2.9% wk 73 · n 242 · Phase 3 · secondary NCT03397121
  • -19.3% vs 1.7% wk 51.43 · n 92 · Phase 3 · secondary NCT04652726
  • -21.5% vs 4.2% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -21.9% vs 3.9% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -5.8% vs 4.5% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -25.1% vs 2.2% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -36.6% vs 0.2% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • -0.7% vs 2.8% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -0.8% vs 3.5% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -6.4% vs 6.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -14.8% vs 10.6% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -18.5% vs 4.5% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -20.3% vs 10% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -46.8% vs 3.8% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -50.4% vs 3.9% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -51.9% vs 2.0% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -51.9% vs 3.0% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -46.8% vs 2.8% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -48.5% vs 1.4% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -48.8% vs 2.2% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -37.1% vs 1.1% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -44.5% vs 3.8% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -46.7% vs 3.9% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -48.2% vs 2.0% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -47.0% vs 3.0% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -42.0% vs 2.8% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -44.5% vs 1.4% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -44.0% vs 2.2% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -32.5% vs 1.1% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -38.6% vs 3.8% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -42.8% vs 3.9% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -43.4% vs 2.0% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -40.9% vs 3.0% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -35.8% vs 2.8% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -39.9% vs 1.4% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -39.7% vs 2.2% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -28.2% vs 1.1% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298
Lp(a), % change-27.7% vs -5.4%−22.3 vs placebowk 52 · n 599NCT01516879
52 other results
  • -16.4% vs 10.3% wk 24 · n 302 · Phase 3 · secondary NCT02833844
  • -12.8% vs 1.1% 420 mg QM · wk 16 · n 63 · Phase 3 · secondary NCT02729025
  • -25.9% vs 11.4% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -20.3% vs 11.4% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -24.6% vs 11.4% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -24.7% vs 11.4% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -25.1% vs 11.4% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -20.9% vs 11.4% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -26.1% vs 11.4% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -22.0% vs 11.4% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -38.1% vs 11.4% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -29.2% vs 11.4% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -20.4% vs 0% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -17.8% vs 0% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -25.2% vs 7.4% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -42.3% vs 16.9% QM · n 332 · Phase 3 · secondary NCT02662569
  • -22.9% vs 6.7% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -21.6% vs 6.7% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -35.9% vs 26.5% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -37.9% vs 26.5% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -45.7% vs 10.8% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -41.7% vs 10.8% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -41.9% vs 10.8% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -45.7% vs 10.8% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -45.0% vs 6.5% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -49.5% vs 6.5% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -26.0% vs 11.4% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -22.6% vs 11.4% QM · n 110 · Phase 3 · secondary NCT01763866
  • -24.0% vs 11.4% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -27.5% vs 11.4% QM · n 110 · Phase 3 · secondary NCT01763866
  • -24.3% vs 11.4% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -23.2% vs 11.4% QM · n 115 · Phase 3 · secondary NCT01763866
  • -25.0% vs 11.4% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -25.9% vs 11.4% QM · n 112 · Phase 3 · secondary NCT01763866
  • -38.6% vs 11.4% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -32.2% vs 11.4% QM · n 115 · Phase 3 · secondary NCT01763866
  • -18.4% vs 0% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -19.2% vs 0% QM · n 153 · Phase 3 · secondary NCT01763827
  • -24.0% vs 5.3% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -25.6% vs 5.3% QM · n 110 · Phase 3 · secondary NCT01763918
  • -38.6% vs 16.9% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -30.9% vs 9.6% n 280 · Phase 3 · secondary NCT02739984
  • -9.4% vs 2.4% wk 12 · n 33 · Phase 2/3 · secondary NCT01588496
  • -46.0% vs 6.5% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -43.0% vs 6.5% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -12.7% vs -1.4% n 33 · Phase 2/3 · secondary NCT01588496
  • -21.1% vs 0.2% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -27.0% vs -1.7% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -22.1% vs -1.7% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -22.7% vs -1.6% n 145 · Phase 3 · secondary NCT01984424
  • -26.2% vs -2.3% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -23.7% vs -2.3% QM · n 102 · Phase 3 · secondary NCT01763905
-9.3% vs 3.6%−12.9 vs placebowk 51.43 · n 92NCT04652726
34 other results
  • -5.0% vs 1.1% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -7.2% vs 1.1% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -4.8% vs 4.9% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -13.4% vs 5.4% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -23.8% vs 6.4% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • -3.8% vs 15.2% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -4.6% vs 4.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -1.7% vs -12.1% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -0.3% vs -16.5% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -0.7% vs -4.4% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -35.4% vs 5.5% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -38.1% vs 4.0% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -37.2% vs 0.2% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -37.9% vs -2.4% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -34.3% vs 4.3% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -36.2% vs -4.3% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -31.3% vs 0.9% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -22.8% vs 3.3% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -25.5% vs 5.5% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -21.6% vs 4.0% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -30.3% vs 0.2% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -26.0% vs -2.4% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -24.9% vs 4.3% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -26.1% vs -4.3% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -22.8% vs 0.9% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -16.6% vs 3.3% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -30.1% vs 5.5% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -32.2% vs 4.0% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -31.5% vs 0.2% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -32.0% vs -2.4% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -27.1% vs 4.3% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -30.9% vs -4.3% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -28.1% vs 0.9% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -21.8% vs 3.3% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298
3-point MACE (% with event)7.9% vs 9.9%−2 vs placebowk 156 · n 13784NCT01764633
5 other results
  • 6.7% vs 8.3% wk 130 · n 13784 · Phase 3 · secondary NCT01764633
  • 5.5% vs 6.8% wk 104 · n 13784 · Phase 3 · secondary NCT01764633
  • 4.3% vs 5.2% wk 78 · n 13784 · Phase 3 · secondary NCT01764633
  • 3.1% vs 3.7% wk 52 · n 13784 · Phase 3 · secondary NCT01764633
  • 1.6% vs 1.9% wk 26 · n 13784 · Phase 3 · secondary NCT01764633
—Not posted · NCT05004675

LDL-C, % change

Evolocumab
-50.1% vs 6.8%−57 vs placebowk 52 · n 599NCT01516879
57 other results
  • -44.5% vs -6.2% 420 mg QM · wk 24 · n 104 · Phase 3 · primary NCT02392559
  • -55.2% vs 1.7% wk 24 · n 295 · Phase 3 · primary NCT02833844
  • -61.6% vs 8.1% Q2W · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -58.2% vs 8.1% QM · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -61.8% vs 8.1% Q2W · wk 12 · n 109 · Phase 3 · primary NCT01763866
  • -58.7% vs 8.1% QM · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -60.1% vs 8.1% Q2W · wk 12 · n 113 · Phase 3 · primary NCT01763866
  • -59.4% vs 8.1% QM · wk 12 · n 115 · Phase 3 · primary NCT01763866
  • -58.9% vs 8.1% Q2W · wk 12 · n 111 · Phase 3 · primary NCT01763866
  • -52.4% vs 8.1% QM · wk 12 · n 112 · Phase 3 · primary NCT01763866
  • -65.9% vs 8.1% Q2W · wk 12 · n 112 · Phase 3 · primary NCT01763866
  • -57.0% vs 8.1% QM · wk 12 · n 115 · Phase 3 · primary NCT01763866
  • -57.0% vs -1.3% Q2W · wk 12 · n 153 · Phase 3 · primary NCT01763827
  • -56.1% vs -1.3% QM · wk 12 · n 153 · Phase 3 · primary NCT01763827
  • -62.3% vs 7.1% QM · wk 12 · n 332 · Phase 3 · primary NCT02662569
  • -54.3% vs -1.1% wk 12 · n 280 · Phase 3 · primary NCT02739984
  • -69.0% vs 4.9% QM · n 332 · Phase 3 · primary NCT02662569
  • -61.3% vs 5.5% Q2W · wk 12 · n 110 · Phase 3 · primary NCT01763918
  • -55.7% vs 5.5% QM · wk 12 · n 110 · Phase 3 · primary NCT01763918
  • -64.7% vs 7.1% Q2W · wk 12 · n 325 · Phase 3 · primary NCT02662569
  • -73.6% vs 1.4% Q2W · wk 12 · n 50 · Phase 3 · primary NCT01953328
  • -64.6% vs 1.4% QM · wk 12 · n 50 · Phase 3 · primary NCT01953328
  • -74.5% vs 1.4% Q2W · wk 12 · n 51 · Phase 3 · primary NCT01953328
  • -70.4% vs 1.4% QM · wk 12 · n 51 · Phase 3 · primary NCT01953328
  • -73.7% vs -0.4% Q2W · wk 11 · n 50 · Phase 3 · primary NCT01953328
  • -70.0% vs -0.4% QM · wk 11 · n 50 · Phase 3 · primary NCT01953328
  • -74.8% vs -0.4% Q2W · wk 11 · n 51 · Phase 3 · primary NCT01953328
  • -76.9% vs -0.4% QM · wk 11 · n 51 · Phase 3 · primary NCT01953328
  • -61.4% vs 7.5% Q2W · n 110 · Phase 3 · primary NCT01763866
  • -62.5% vs 7.5% QM · n 110 · Phase 3 · primary NCT01763866
  • -61.8% vs 7.5% Q2W · n 109 · Phase 3 · primary NCT01763866
  • -65.0% vs 7.5% QM · n 110 · Phase 3 · primary NCT01763866
  • -59.3% vs 7.5% Q2W · n 113 · Phase 3 · primary NCT01763866
  • -63.8% vs 7.5% QM · n 115 · Phase 3 · primary NCT01763866
  • -59.1% vs 7.5% Q2W · n 111 · Phase 3 · primary NCT01763866
  • -62.9% vs 7.5% QM · n 112 · Phase 3 · primary NCT01763866
  • -66.2% vs 7.5% Q2W · n 112 · Phase 3 · primary NCT01763866
  • -62.5% vs 7.5% QM · n 115 · Phase 3 · primary NCT01763866
  • -56.9% vs -1.4% Q2W · n 153 · Phase 3 · primary NCT01763827
  • -58.8% vs -1.4% QM · n 153 · Phase 3 · primary NCT01763827
  • -61.2% vs 2.3% Q2W · n 110 · Phase 3 · primary NCT01763918
  • -63.3% vs 2.3% QM · n 110 · Phase 3 · primary NCT01763918
  • -65.3% vs 4.9% Q2W · n 325 · Phase 3 · primary NCT02662569
  • -65.0% vs -0.8% n 280 · Phase 3 · primary NCT02739984
  • -23.1% vs 7.9% wk 12 · n 33 · Phase 2/3 · primary NCT01588496
  • -52.8% vs -16.7% wk 24 · n 145 · Phase 3 · primary NCT01984424
  • -56.1% vs -18.1% Q2W · wk 12 · n 103 · Phase 3 · primary NCT01763905
  • -52.6% vs -18.1% QM · wk 12 · n 102 · Phase 3 · primary NCT01763905
  • -54.5% vs -16.7% n 145 · Phase 3 · primary NCT01984424
  • -56.1% vs -19.2% Q2W · n 103 · Phase 3 · primary NCT01763905
  • -55.3% vs -19.2% QM · n 102 · Phase 3 · primary NCT01763905
  • -54.4% vs 3.2% wk 12 · n 599 · Phase 3 · secondary NCT01516879
  • -59.0% vs 1.6% 420 mg QM · wk 16 · n 62 · Phase 3 · secondary NCT02729025
  • -48.0% vs -5.9% 420 mg QM · n 104 · Phase 3 · secondary NCT02392559
  • -57.8% vs -0.7% wk 7.14 · n 18 · Phase 3 · secondary NCT02189837
  • -83.2% vs -0.7% wk 7.14 · n 17 · Phase 3 · secondary NCT02189837
  • -25.6% vs 4.2% n 33 · Phase 2/3 · secondary NCT01588496
Inclisiran
-49.3% vs 4.2%−53.5 vs placebowk 72.9 · n 810NCT03400800
76 other results
  • -56.3% vs 1.3% wk 72.9 · n 781 · Phase 3 · primary NCT03399370
  • -45.8% vs 3.4% n 810 · Phase 3 · primary NCT03400800
  • -51.3% vs 2.5% n 781 · Phase 3 · primary NCT03399370
  • -41.1% vs 8.4% wk 73 · n 242 · Phase 3 · primary NCT03397121
  • -27.1% vs 1.4% wk 47.14 · n 93 · Phase 3 · primary NCT04652726
  • -45.9% vs 1.6% wk 21.43 · n 103 · Phase 3 · primary NCT05888103
  • -38.1% vs 6.2% n 242 · Phase 3 · primary NCT03397121
  • 0.7% vs 2.4% wk 21.43 · n 37 · Phase 3 · primary NCT03851705
  • -21.6% vs 11.7% wk 47.14 · n 9 · Phase 3 · primary NCT04659863
  • -45.6% vs 1.4% wk 47 · n 171 · Phase 3 · primary NCT04873934
  • -60% vs -7% wk 47 · n 205 · Phase 3 · primary NCT04929249
  • -26.1% vs 1.5% wk 51.43 · n 93 · Phase 3 · secondary NCT04652726
  • -26.0% vs 3.3% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -27.8% vs 1.5% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -19% vs 2.1% wk 38.57 · n 93 · Phase 3 · secondary NCT04652726
  • -7.2% vs -1.5% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -32.5% vs 6.4% wk 21.43 · n 93 · Phase 3 · secondary NCT04652726
  • 1.8% vs -2.9% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -23.9% vs -0.1% wk 12.86 · n 93 · Phase 3 · secondary NCT04652726
  • -8.7% vs 3.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -19.3% vs 5.4% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -21.6% vs 11.7% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -17.3% vs 10.2% wk 38.57 · n 9 · Phase 3 · secondary NCT04659863
  • -24.1% vs 17% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -26.1% vs 6.8% wk 12.86 · n 9 · Phase 3 · secondary NCT04659863
  • -44.3% vs 2.4% n 194 · Phase 3 · secondary NCT04873934
  • -57.2% vs -2.8% n 222 · Phase 3 · secondary NCT04929249
  • -56.3% vs 9% 300 mg · wk 25.714 · n 96 · Phase 2 · primary NCT04666298
  • -38.4% vs 2.1% 300 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -52.6% vs 2.1% 300 mg double dose · wk 25.71 · n 59 · Phase 2 · primary NCT02597127
  • -41.9% vs 2.1% 500 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -51.9% vs 9% 200 mg · wk 25.714 · n 101 · Phase 2 · primary NCT04666298
  • -27.9% vs 2.1% 200 mg single dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -44.9% vs 2.1% 200 mg double dose · wk 25.71 · n 60 · Phase 2 · primary NCT02597127
  • -47.6% vs 9% 100 mg · wk 25.714 · n 55 · Phase 2 · primary NCT04666298
  • -35.5% vs 2.1% 100 mg double dose · wk 25.71 · n 59 · Phase 2 · primary NCT02597127
  • -59.5% vs -24.3% wk 51.4 · n 898 · Phase 4 · secondary NCT05192941
  • -35.4% vs 1.4% 300 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -50.5% vs 1.4% 300 mg double dose · wk 30 · n 59 · Phase 2 · secondary NCT02597127
  • -66.2% vs 4.3% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -67.2% vs 2.3% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -43.3% vs -0.9% 300 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -54.7% vs -0.9% 300 mg double dose · wk 17.14 · n 59 · Phase 2 · secondary NCT02597127
  • -65.7% vs 1.2% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -61.5% vs 2.7% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -62.4% vs 0.2% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -50.9% vs -4.3% 300 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -51.0% vs -4.3% 300 mg double dose · wk 8.57 · n 59 · Phase 2 · secondary NCT02597127
  • -62.8% vs 1.3% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -47.6% vs 1.7% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -39.2% vs 1.4% 500 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -46.4% vs -0.9% 500 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -49.6% vs -4.3% 500 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -29.0% vs 1.4% 200 mg single dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -42.6% vs 1.4% 200 mg double dose · wk 30 · n 60 · Phase 2 · secondary NCT02597127
  • -60.5% vs 4.3% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -62.0% vs 2.3% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -36.9% vs -0.9% 200 mg single dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -49.5% vs -0.9% 200 mg double dose · wk 17.14 · n 60 · Phase 2 · secondary NCT02597127
  • -60.3% vs 1.2% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -53.9% vs 2.7% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -55.6% vs 0.2% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -44.3% vs -4.3% 200 mg single dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -44.3% vs -4.3% 200 mg double dose · wk 8.57 · n 60 · Phase 2 · secondary NCT02597127
  • -55.5% vs 1.3% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -42.1% vs 1.7% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -31.7% vs 1.4% 100 mg double dose · wk 30 · n 59 · Phase 2 · secondary NCT02597127
  • -55.5% vs 4.3% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -54.9% vs 2.3% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -41.4% vs -0.9% 100 mg double dose · wk 17.14 · n 59 · Phase 2 · secondary NCT02597127
  • -53% vs 1.2% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -46.4% vs 2.7% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -50.1% vs 0.2% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -35.7% vs -4.3% 100 mg double dose · wk 8.57 · n 59 · Phase 2 · secondary NCT02597127
  • -52.2% vs 1.3% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -37.1% vs 1.7% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298

Non-HDL-C, % change

Evolocumab
-41.8% vs 8.4%−50.3 vs placebowk 52 · n 599NCT01516879
50 other results
  • -41.2% vs -6.1% 420 mg QM · wk 24 · n 104 · Phase 3 · secondary NCT02392559
  • -48.1% vs 2.9% wk 24 · n 296 · Phase 3 · secondary NCT02833844
  • -53.4% vs 7.9% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -52.2% vs 7.9% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -54.8% vs 7.9% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -50.0% vs 7.9% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -52.0% vs 7.9% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -51.6% vs 7.9% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -51.0% vs 7.9% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -46.4% vs 7.9% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -59.0% vs 7.9% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -51.0% vs 7.9% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -50.1% vs 1.5% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -49.7% vs 1.5% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -52.9% vs 5.9% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -59.1% vs 4.3% QM · n 332 · Phase 3 · secondary NCT02662569
  • -56.2% vs 5.3% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -49.7% vs 5.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -55.8% vs 5.9% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -46.9% vs -0.6% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -67.8% vs -0.1% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -58.0% vs -0.1% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -68.9% vs -0.1% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -63.3% vs -0.1% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -68.5% vs -1.6% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -61.7% vs -1.6% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -69.7% vs -1.6% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -69.1% vs -1.6% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -53.5% vs 7.0% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -56.1% vs 7.0% QM · n 110 · Phase 3 · secondary NCT01763866
  • -54.4% vs 7.0% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -56.3% vs 7.0% QM · n 110 · Phase 3 · secondary NCT01763866
  • -52.6% vs 7.0% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -55.5% vs 7.0% QM · n 115 · Phase 3 · secondary NCT01763866
  • -52.1% vs 7.0% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -55.7% vs 7.0% QM · n 112 · Phase 3 · secondary NCT01763866
  • -59.3% vs 7.0% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -56.0% vs 7.0% QM · n 115 · Phase 3 · secondary NCT01763866
  • -50.2% vs 1.3% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -52.0% vs 1.3% QM · n 153 · Phase 3 · secondary NCT01763827
  • -55.8% vs 2.7% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -57.3% vs 2.7% QM · n 110 · Phase 3 · secondary NCT01763918
  • -56.6% vs 4.3% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -56.6% vs -0.1% n 280 · Phase 3 · secondary NCT02739984
  • -45.7% vs -14.6% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -48.6% vs -16.5% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -46.1% vs -16.5% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -47.4% vs -14.4% n 145 · Phase 3 · secondary NCT01984424
  • -48.7% vs -17.2% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -49.1% vs -17.2% QM · n 102 · Phase 3 · secondary NCT01763905
Inclisiran
-41.2% vs 2.1%−43.3 vs placebowk 72.9 · n 810NCT03400800
38 other results
  • -47.4% vs -0.1% wk 72.9 · n 781 · Phase 3 · secondary NCT03399370
  • -34.9% vs 7.4% wk 73 · n 242 · Phase 3 · secondary NCT03397121
  • -24% vs 1.2% wk 51.43 · n 92 · Phase 3 · secondary NCT04652726
  • -25.0% vs 1.8% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -25.7% vs 1.8% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -6.2% vs -1.1% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -29% vs 5.1% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -40.7% vs -0.1% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • 1.3% vs -1.7% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • 0.4% vs 2.5% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -7.2% vs 2.9% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -20.1% vs 7.1% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -23.3% vs 9.4% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -24% vs 19% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -54.0% vs 1.3% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -56.8% vs 2.0% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -58.7% vs 0.8% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -57.7% vs 2.0% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -53.2% vs 1.8% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -54.1% vs 0.6% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -54.2% vs 1.0% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -41.2% vs 1.1% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -50.1% vs 1.3% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -52.9% vs 2.0% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -53.5% vs 0.8% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -52.0% vs 2.0% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -47.2% vs 1.8% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -48.2% vs 0.6% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -48.0% vs 1.0% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -35.7% vs 1.1% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -44.8% vs 1.3% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -47.9% vs 2.0% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -48.2% vs 0.8% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -46.1% vs 2.0% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -39.8% vs 1.8% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -43.4% vs 0.6% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -44.7% vs 1.0% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -31.4% vs 1.1% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298

ApoB, % change

Evolocumab
-41.3% vs 2.9%−44.2 vs placebowk 52 · n 599NCT01516879
53 other results
  • -34.9% vs -2.4% 420 mg QM · wk 24 · n 104 · Phase 3 · secondary NCT02392559
  • -45.1% vs 2.6% wk 24 · n 302 · Phase 3 · secondary NCT02833844
  • -48.3% vs 3.3% 420 mg QM · wk 16 · n 63 · Phase 3 · secondary NCT02729025
  • -50.9% vs 6.3% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -47.1% vs 6.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -49.8% vs 6.3% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -46.5% vs 6.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -50.1% vs 6.3% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -48.6% vs 6.3% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -45.6% vs 6.3% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -43.7% vs 6.3% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -56.0% vs 6.3% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -49.2% vs 6.3% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -47.2% vs 1.8% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -46.6% vs 1.8% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -49.7% vs 3.2% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -56.4% vs 2.0% QM · n 332 · Phase 3 · secondary NCT02662569
  • -49.8% vs 4.6% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -44.8% vs 4.6% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -53.9% vs 3.2% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -40.3% vs 1.8% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -64.8% vs -2.5% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -54.8% vs -2.5% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -62.8% vs -2.5% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -64.4% vs -4.3% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -51.0% vs 5.1% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -51.4% vs 5.1% QM · n 110 · Phase 3 · secondary NCT01763866
  • -49.1% vs 5.1% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -53.3% vs 5.1% QM · n 110 · Phase 3 · secondary NCT01763866
  • -49.8% vs 5.1% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -53.6% vs 5.1% QM · n 115 · Phase 3 · secondary NCT01763866
  • -47.1% vs 5.1% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -53.0% vs 5.1% QM · n 112 · Phase 3 · secondary NCT01763866
  • -55.6% vs 5.1% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -54.4% vs 5.1% QM · n 115 · Phase 3 · secondary NCT01763866
  • -47.0% vs 1.5% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -49.4% vs 1.5% QM · n 153 · Phase 3 · secondary NCT01763827
  • -49.6% vs 2.2% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -52.8% vs 2.2% QM · n 110 · Phase 3 · secondary NCT01763918
  • -55.0% vs 2.0% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -50.2% vs 2.3% n 280 · Phase 3 · secondary NCT02739984
  • -19.2% vs 4.0% wk 12 · n 33 · Phase 2/3 · secondary NCT01588496
  • -58.0% vs -2.5% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -64.8% vs -4.3% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -58.5% vs -4.3% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -64.2% vs -4.3% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -20.2% vs 2.6% n 33 · Phase 2/3 · secondary NCT01588496
  • -43.5% vs -11.7% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -45.8% vs -12.9% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -43.1% vs -12.9% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -45.3% vs -11.4% n 145 · Phase 3 · secondary NCT01984424
  • -45.9% vs -13.7% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -46.0% vs -13.7% QM · n 102 · Phase 3 · secondary NCT01763905
Inclisiran
-38.1% vs 0.8%−38.9 vs placebowk 72.9 · n 810NCT03400800
38 other results
  • -44.8% vs -1.7% wk 72.9 · n 781 · Phase 3 · secondary NCT03399370
  • -33.1% vs 2.9% wk 73 · n 242 · Phase 3 · secondary NCT03397121
  • -19.3% vs 1.7% wk 51.43 · n 92 · Phase 3 · secondary NCT04652726
  • -21.5% vs 4.2% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -21.9% vs 3.9% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -5.8% vs 4.5% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -25.1% vs 2.2% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -36.6% vs 0.2% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • -0.7% vs 2.8% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -0.8% vs 3.5% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -6.4% vs 6.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -14.8% vs 10.6% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -18.5% vs 4.5% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -20.3% vs 10% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -46.8% vs 3.8% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -50.4% vs 3.9% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -51.9% vs 2.0% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -51.9% vs 3.0% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -46.8% vs 2.8% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -48.5% vs 1.4% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -48.8% vs 2.2% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -37.1% vs 1.1% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -44.5% vs 3.8% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -46.7% vs 3.9% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -48.2% vs 2.0% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -47.0% vs 3.0% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -42.0% vs 2.8% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -44.5% vs 1.4% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -44.0% vs 2.2% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -32.5% vs 1.1% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -38.6% vs 3.8% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -42.8% vs 3.9% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -43.4% vs 2.0% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -40.9% vs 3.0% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -35.8% vs 2.8% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -39.9% vs 1.4% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -39.7% vs 2.2% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -28.2% vs 1.1% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298

Lp(a), % change

Evolocumab
-27.7% vs -5.4%−22.3 vs placebowk 52 · n 599NCT01516879
52 other results
  • -16.4% vs 10.3% wk 24 · n 302 · Phase 3 · secondary NCT02833844
  • -12.8% vs 1.1% 420 mg QM · wk 16 · n 63 · Phase 3 · secondary NCT02729025
  • -25.9% vs 11.4% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -20.3% vs 11.4% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -24.6% vs 11.4% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -24.7% vs 11.4% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -25.1% vs 11.4% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -20.9% vs 11.4% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -26.1% vs 11.4% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -22.0% vs 11.4% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -38.1% vs 11.4% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -29.2% vs 11.4% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -20.4% vs 0% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -17.8% vs 0% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -25.2% vs 7.4% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -42.3% vs 16.9% QM · n 332 · Phase 3 · secondary NCT02662569
  • -22.9% vs 6.7% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -21.6% vs 6.7% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -35.9% vs 26.5% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -37.9% vs 26.5% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -45.7% vs 10.8% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -41.7% vs 10.8% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -41.9% vs 10.8% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -45.7% vs 10.8% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -45.0% vs 6.5% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -49.5% vs 6.5% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -26.0% vs 11.4% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -22.6% vs 11.4% QM · n 110 · Phase 3 · secondary NCT01763866
  • -24.0% vs 11.4% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -27.5% vs 11.4% QM · n 110 · Phase 3 · secondary NCT01763866
  • -24.3% vs 11.4% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -23.2% vs 11.4% QM · n 115 · Phase 3 · secondary NCT01763866
  • -25.0% vs 11.4% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -25.9% vs 11.4% QM · n 112 · Phase 3 · secondary NCT01763866
  • -38.6% vs 11.4% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -32.2% vs 11.4% QM · n 115 · Phase 3 · secondary NCT01763866
  • -18.4% vs 0% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -19.2% vs 0% QM · n 153 · Phase 3 · secondary NCT01763827
  • -24.0% vs 5.3% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -25.6% vs 5.3% QM · n 110 · Phase 3 · secondary NCT01763918
  • -38.6% vs 16.9% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -30.9% vs 9.6% n 280 · Phase 3 · secondary NCT02739984
  • -9.4% vs 2.4% wk 12 · n 33 · Phase 2/3 · secondary NCT01588496
  • -46.0% vs 6.5% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -43.0% vs 6.5% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -12.7% vs -1.4% n 33 · Phase 2/3 · secondary NCT01588496
  • -21.1% vs 0.2% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -27.0% vs -1.7% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -22.1% vs -1.7% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -22.7% vs -1.6% n 145 · Phase 3 · secondary NCT01984424
  • -26.2% vs -2.3% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -23.7% vs -2.3% QM · n 102 · Phase 3 · secondary NCT01763905
Inclisiran
-9.3% vs 3.6%−12.9 vs placebowk 51.43 · n 92NCT04652726
34 other results
  • -5.0% vs 1.1% wk 47.14 · n 93 · Phase 3 · secondary NCT04652726
  • -7.2% vs 1.1% wk 47.14 · n 92 · Phase 3 · secondary NCT04652726
  • -4.8% vs 4.9% wk 25.71 · n 37 · Phase 3 · secondary NCT03851705
  • -13.4% vs 5.4% wk 21.43 · n 92 · Phase 3 · secondary NCT04652726
  • -23.8% vs 6.4% wk 21.43 · n 103 · Phase 3 · secondary NCT05888103
  • -3.8% vs 15.2% wk 21.43 · n 37 · Phase 3 · secondary NCT03851705
  • -4.6% vs 4.3% wk 12.86 · n 37 · Phase 3 · secondary NCT03851705
  • -1.7% vs -12.1% wk 51.43 · n 9 · Phase 3 · secondary NCT04659863
  • -0.3% vs -16.5% wk 47.14 · n 9 · Phase 3 · secondary NCT04659863
  • -0.7% vs -4.4% wk 21.43 · n 9 · Phase 3 · secondary NCT04659863
  • -35.4% vs 5.5% 300 mg · wk 25.71 · n 98 · Phase 2 · secondary NCT04666298
  • -38.1% vs 4.0% 300 mg · wk 21.43 · n 98 · Phase 2 · secondary NCT04666298
  • -37.2% vs 0.2% 300 mg · wk 17.14 · n 98 · Phase 2 · secondary NCT04666298
  • -37.9% vs -2.4% 300 mg · wk 14.86 · n 98 · Phase 2 · secondary NCT04666298
  • -34.3% vs 4.3% 300 mg · wk 12.86 · n 98 · Phase 2 · secondary NCT04666298
  • -36.2% vs -4.3% 300 mg · wk 8.57 · n 98 · Phase 2 · secondary NCT04666298
  • -31.3% vs 0.9% 300 mg · wk 4.29 · n 98 · Phase 2 · secondary NCT04666298
  • -22.8% vs 3.3% 300 mg · wk 2 · n 98 · Phase 2 · secondary NCT04666298
  • -25.5% vs 5.5% 200 mg · wk 25.71 · n 101 · Phase 2 · secondary NCT04666298
  • -21.6% vs 4.0% 200 mg · wk 21.43 · n 101 · Phase 2 · secondary NCT04666298
  • -30.3% vs 0.2% 200 mg · wk 17.14 · n 101 · Phase 2 · secondary NCT04666298
  • -26.0% vs -2.4% 200 mg · wk 14.86 · n 101 · Phase 2 · secondary NCT04666298
  • -24.9% vs 4.3% 200 mg · wk 12.86 · n 101 · Phase 2 · secondary NCT04666298
  • -26.1% vs -4.3% 200 mg · wk 8.57 · n 101 · Phase 2 · secondary NCT04666298
  • -22.8% vs 0.9% 200 mg · wk 4.29 · n 101 · Phase 2 · secondary NCT04666298
  • -16.6% vs 3.3% 200 mg · wk 2 · n 101 · Phase 2 · secondary NCT04666298
  • -30.1% vs 5.5% 100 mg · wk 25.71 · n 55 · Phase 2 · secondary NCT04666298
  • -32.2% vs 4.0% 100 mg · wk 21.43 · n 55 · Phase 2 · secondary NCT04666298
  • -31.5% vs 0.2% 100 mg · wk 17.14 · n 55 · Phase 2 · secondary NCT04666298
  • -32.0% vs -2.4% 100 mg · wk 14.86 · n 55 · Phase 2 · secondary NCT04666298
  • -27.1% vs 4.3% 100 mg · wk 12.86 · n 55 · Phase 2 · secondary NCT04666298
  • -30.9% vs -4.3% 100 mg · wk 8.57 · n 55 · Phase 2 · secondary NCT04666298
  • -28.1% vs 0.9% 100 mg · wk 4.29 · n 55 · Phase 2 · secondary NCT04666298
  • -21.8% vs 3.3% 100 mg · wk 2 · n 55 · Phase 2 · secondary NCT04666298

3-point MACE (% with event)

Evolocumab
7.9% vs 9.9%−2 vs placebowk 156 · n 13784NCT01764633
5 other results
  • 6.7% vs 8.3% wk 130 · n 13784 · Phase 3 · secondary NCT01764633
  • 5.5% vs 6.8% wk 104 · n 13784 · Phase 3 · secondary NCT01764633
  • 4.3% vs 5.2% wk 78 · n 13784 · Phase 3 · secondary NCT01764633
  • 3.1% vs 3.7% wk 52 · n 13784 · Phase 3 · secondary NCT01764633
  • 1.6% vs 1.9% wk 26 · n 13784 · Phase 3 · secondary NCT01764633
Inclisiran
—Not posted · NCT05004675
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
12 other shared endpoints and safety

Coverage. Evolocumab: 16 of 16 rows · Inclisiran: 16 of 16 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEvolocumab
Rows use multiple source trials
Inclisiran
Rows use multiple source trials
Apo B
percent change · % of baseline
No placebo or comparator arm
-22.68% (n=106) @ 216wka,b,c,d
NCT01624142 · Phase 2/3
-33.66% (n=277) @ 205.71wka,b,c,d
NCT03060577 · Phase 2 · registry result, not featured evidence
HDL-C
percent change · % of baseline
5.77% (n=599) vs 0.35% (n=302) placebo @ 52wke,f,g
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
20 other source trials
5.54% (n=110) vs -0.99% (n=56) placeboQ2W
NCT01763866 · Phase 3
7.66% (n=110) vs -0.99% (n=56) placeboQM
NCT01763866 · Phase 3
8.44% (n=109) vs -0.99% (n=56) placeboQ2W
NCT01763866 · Phase 3
7.76% (n=110) vs -0.99% (n=56) placeboQM
NCT01763866 · Phase 3
4.86% (n=111) vs -0.99% (n=56) placeboQ2W
NCT01763866 · Phase 3
6.35% (n=112) vs -0.99% (n=56) placeboQM
NCT01763866 · Phase 3
6.23% (n=113) vs -0.99% (n=56) placeboQ2W
NCT01763866 · Phase 3
7.72% (n=115) vs -0.99% (n=56) placeboQM
NCT01763866 · Phase 3
10.35% (n=112) vs -0.99% (n=56) placeboQ2W
NCT01763866 · Phase 3
6.71% (n=115) vs -0.99% (n=56) placeboQM
NCT01763866 · Phase 3
3.89% (n=153) vs -1.64% (n=76) placeboQ2W
NCT01763827 · Phase 3
3.81% (n=153) vs -1.64% (n=76) placeboQM
NCT01763827 · Phase 3
7.93% (n=110) vs -0.45% (n=54) placeboQ2W
NCT01763918 · Phase 3
6.62% (n=110) vs -0.45% (n=54) placeboQM
NCT01763918 · Phase 3
7.59% (n=325) vs 1.25% (n=164) placeboQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
13.75% (n=332) vs 1.25% (n=164) placeboQM
NCT02662569 · Phase 3 · registry result, not featured evidence
7.85% (n=145) vs 1.66% (n=73) Ezetimibe
NCT01984424 · Phase 3 · registry result, not featured evidence
7.23% (n=280) vs -2.57% (n=141) placebo
NCT02739984 · Phase 3 · registry result, not featured evidence
5.48% (n=103) vs 0.33% (n=51) EzetimibeQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
7.18% (n=102) vs 0.33% (n=51) EzetimibeQM
NCT01763905 · Phase 3 · registry result, not featured evidence
4.4% (n=92) vs 0.9% (n=48) placebo @ 51.43wke,f,g
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
LDL-C
absolute change · mg/dL
-52.7 vs 5.1 placebo mg/dL @ 52wkh,f
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
20 other source trials
-76.8 vs 6.8 placebo mg/dLQ2W
NCT01763866 · Phase 3
-80.1 vs 6.8 placebo mg/dLQM
NCT01763866 · Phase 3
-58.8 vs 6.8 placebo mg/dLQ2W
NCT01763866 · Phase 3
-60.1 vs 6.8 placebo mg/dLQM
NCT01763866 · Phase 3
-52.3 vs 6.8 placebo mg/dLQ2W
NCT01763866 · Phase 3
-55.3 vs 6.8 placebo mg/dLQM
NCT01763866 · Phase 3
-68.9 vs 6.8 placebo mg/dLQ2W
NCT01763866 · Phase 3
-77.8 vs 6.8 placebo mg/dLQM
NCT01763866 · Phase 3
-83.8 vs 6.8 placebo mg/dLQ2W
NCT01763866 · Phase 3
-78.4 vs 6.8 placebo mg/dLQM
NCT01763866 · Phase 3
-78.4 vs 1.2 placebo mg/dLQ2W
NCT01763827 · Phase 3
-81.9 vs 1.2 placebo mg/dLQM
NCT01763827 · Phase 3
-101.7 vs -6.5 placebo mg/dLQ2W
NCT01763918 · Phase 3
-98.8 vs -6.5 placebo mg/dLQM
NCT01763918 · Phase 3
-64.6 vs -2.1 placebo mg/dLQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-71.9 vs -2.1 placebo mg/dLQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-106.8 vs -31 Ezetimibe mg/dL
NCT01984424 · Phase 3 · registry result, not featured evidence
-75.5 vs -8.3 placebo mg/dL
NCT02739984 · Phase 3 · registry result, not featured evidence
-105.4 vs -39.1 Ezetimibe mg/dLQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-103.6 vs -39.1 Ezetimibe mg/dLQM
NCT01763905 · Phase 3 · registry result, not featured evidence
-50.91 vs 0.96 placebo mg/dL @ 72.9wki,h,f
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 1 more dose
-48.63 vs 0.31 placebo mg/dL
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
LDL-C
percent change · % of baseline
No placebo or comparator arm
-32.22% (n=106) @ 216wka,b,c,d
NCT01624142 · Phase 2/3
2 other source trials
-64.5% (n=82)
NCT01879319 · Phase 3 · registry result, not featured evidence
-67.9% (n=82)
NCT01879319 · Phase 3 · registry result, not featured evidence
-46.74% (n=277) @ 205.71wka,b,c,d
NCT03060577 · Phase 2 · registry result, not featured evidence
LDL-C
absolute change · mg/dL
No placebo or comparator arm
-63.1 mg/dL @ 80wk420 mg QMi,j,b,c,k
NCT02624869 · Phase 3
show 2 more doses
-67.2 mg/dL @ 80wk420 mg QM
NCT02624869 · Phase 3
-36.5 mg/dL @ 80wk420 mg QM
NCT02624869 · Phase 3
-60.04 mg/dL @ 205.71wkj,b,c,k
NCT03060577 · Phase 2 · registry result, not featured evidence
LDL-C
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
-47.94% (n=770) @ 104wkb,c,l
NCT02304484 · Phase 3 · registry result, not featured evidence
-45.45% (n=103) @ 47.14wkb,c,l
NCT05888103 · Phase 3 · registry result, not featured evidence
LDL-C Less Than 70
responder rate · % of participants
88.1% (n=110) vs 5.7% (n=56) placeboQ2Wi,m,c,n
NCT01763866 · Phase 3
show 9 more doses
85.8% (n=110) vs 5.7% (n=56) placeboQM
NCT01763866 · Phase 3
94.4% (n=109) vs 5.7% (n=56) placeboQ2W
NCT01763866 · Phase 3
92.5% (n=110) vs 5.7% (n=56) placeboQM
NCT01763866 · Phase 3
93.5% (n=111) vs 5.7% (n=56) placeboQ2W
NCT01763866 · Phase 3
94.5% (n=112) vs 5.7% (n=56) placeboQM
NCT01763866 · Phase 3
88.7% (n=113) vs 5.7% (n=56) placeboQ2W
NCT01763866 · Phase 3
89.9% (n=115) vs 5.7% (n=56) placeboQM
NCT01763866 · Phase 3
93.6% (n=112) vs 5.7% (n=56) placeboQ2W
NCT01763866 · Phase 3
88.5% (n=115) vs 5.7% (n=56) placeboQM
NCT01763866 · Phase 3
66.7% (n=201) vs 28.1% (n=199) Usual Care @ 47wkm,c,n
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
1 other source trial
81.8% (n=225) vs 22.2% (n=225) Usual Care @ 47wk
NCT04929249 · Phase 3 · registry result, not featured evidence
Lp(a
percent change · % of baseline
No placebo or comparator arm
-14.06% (n=106) @ 216wka,b,c,d
NCT01624142 · Phase 2/3
-5.24% (n=277) @ 205.71wka,b,c,d
NCT03060577 · Phase 2 · registry result, not featured evidence
Non-HDL-C
percent change · % of baseline
No placebo or comparator arm
-31.4% (n=106) @ 216wko,b,c,p
NCT01624142 · Phase 2/3
-13% (n=13) @ 102.86wko,b,c,p
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
1 other source trial
-5% (n=34) @ 102.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
Total Cholesterol
percent change · % of baseline
-28.18% (n=599) vs 5.26% (n=302) placebo @ 52wkh,f,q
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
4 other source trials
-38.64% (n=325) vs 2.89% (n=164) placeboQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-39.74% (n=332) vs 2.89% (n=164) placeboQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-38.04% (n=145) vs -11.43% (n=73) Ezetimibe
NCT01984424 · Phase 3 · registry result, not featured evidence
-42.19% (n=280) vs -1.13% (n=141) placebo
NCT02739984 · Phase 3 · registry result, not featured evidence
-28% (n=810) vs 1.79% (n=807) placebo @ 72.9wkh,f,q
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
1 other source trial
-33.56% (n=781) vs -0.42% (n=781) placebo @ 72.9wk
NCT03399370 · Phase 3
Triglycerides
percent change · % of baseline
-2.55% (n=599) vs 8.99% (n=302) placebo @ 52wke,f,g
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
20 other source trials
-5.61% (n=110) vs 6.49% (n=56) placeboQ2W
NCT01763866 · Phase 3
-13.38% (n=110) vs 6.49% (n=56) placeboQM
NCT01763866 · Phase 3
-9.27% (n=109) vs 6.49% (n=56) placeboQ2W
NCT01763866 · Phase 3
-6.36% (n=110) vs 6.49% (n=56) placeboQM
NCT01763866 · Phase 3
-9.15% (n=111) vs 6.49% (n=56) placeboQ2W
NCT01763866 · Phase 3
-15.43% (n=112) vs 6.49% (n=56) placeboQM
NCT01763866 · Phase 3
-10.28% (n=113) vs 6.49% (n=56) placeboQ2W
NCT01763866 · Phase 3
-7.26% (n=115) vs 6.49% (n=56) placeboQM
NCT01763866 · Phase 3
-11.67% (n=112) vs 6.49% (n=56) placeboQ2W
NCT01763866 · Phase 3
-15.93% (n=115) vs 6.49% (n=56) placeboQM
NCT01763866 · Phase 3
-9.16% (n=153) vs -3.89% (n=76) placeboQ2W
NCT01763827 · Phase 3
-15.71% (n=153) vs -3.89% (n=76) placeboQM
NCT01763827 · Phase 3
-13.27% (n=110) vs 9.09% (n=54) placeboQ2W
NCT01763918 · Phase 3
-9.25% (n=110) vs 9.09% (n=54) placeboQM
NCT01763918 · Phase 3
-6.48% (n=325) vs 11.54% (n=164) placeboQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-7.15% (n=332) vs 11.54% (n=164) placeboQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-5.39% (n=145) vs -0.95% (n=73) Ezetimibe
NCT01984424 · Phase 3 · registry result, not featured evidence
-12.64% (n=280) vs 6.61% (n=141) placebo
NCT02739984 · Phase 3 · registry result, not featured evidence
-6.32% (n=103) vs -3.74% (n=51) EzetimibeQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-6.73% (n=102) vs -3.74% (n=51) EzetimibeQM
NCT01763905 · Phase 3 · registry result, not featured evidence
1.7% (n=92) vs 3.8% (n=48) placebo @ 51.43wke,f,g
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
VLDL-C
percent change · % of baseline
2.74% (n=599) vs 31.89% (n=302) placebo @ 52wke,f,g
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
20 other source trials
-6.85% (n=110) vs 6.51% (n=56) placeboQ2W
NCT01763866 · Phase 3
-11.77% (n=110) vs 6.51% (n=56) placeboQM
NCT01763866 · Phase 3
-8.96% (n=109) vs 6.51% (n=56) placeboQ2W
NCT01763866 · Phase 3
-6.38% (n=110) vs 6.51% (n=56) placeboQM
NCT01763866 · Phase 3
-9.09% (n=111) vs 6.51% (n=56) placeboQ2W
NCT01763866 · Phase 3
-15.05% (n=112) vs 6.51% (n=56) placeboQM
NCT01763866 · Phase 3
-12.22% (n=113) vs 6.51% (n=56) placeboQ2W
NCT01763866 · Phase 3
-7.25% (n=115) vs 6.51% (n=56) placeboQM
NCT01763866 · Phase 3
-14.57% (n=112) vs 6.51% (n=56) placeboQ2W
NCT01763866 · Phase 3
-16.5% (n=115) vs 6.51% (n=56) placeboQM
NCT01763866 · Phase 3
-8.4% (n=153) vs -3.81% (n=76) placeboQ2W
NCT01763827 · Phase 3
-16.17% (n=153) vs -3.81% (n=76) placeboQM
NCT01763827 · Phase 3
-13.97% (n=110) vs 8.66% (n=54) placeboQ2W
NCT01763918 · Phase 3
-9.2% (n=110) vs 8.66% (n=54) placeboQM
NCT01763918 · Phase 3
-17.55% (n=325) vs 9.63% (n=164) placeboQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-16.09% (n=332) vs 9.63% (n=164) placeboQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-6.81% (n=145) vs -2.15% (n=73) Ezetimibe
NCT01984424 · Phase 3 · registry result, not featured evidence
-13.64% (n=280) vs 3.42% (n=141) placebo
NCT02739984 · Phase 3 · registry result, not featured evidence
-7.6% (n=103) vs -5.76% (n=51) EzetimibeQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-6.46% (n=102) vs -5.76% (n=51) EzetimibeQM
NCT01763905 · Phase 3 · registry result, not featured evidence
1% (n=92) vs 4.7% (n=48) placebo @ 51.43wke,f,g
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
Dropout rate
5.6%r
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 64 more results
0%Part A: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part A: OL Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: DB Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
0%Part B: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
0.7%
NCT01764633 · Phase 3
3.2%
NCT02207634 · Phase 3
1.8%Q2W
NCT01763866 · Phase 3
2.7%QM
NCT01763866 · Phase 3
7.3%Q2W
NCT01763866 · Phase 3
1.8%QM
NCT01763866 · Phase 3
5.4%Q2W
NCT01763866 · Phase 3
1.8%QM
NCT01763866 · Phase 3
10.5%Q2W
NCT01763866 · Phase 3
2.6%QM
NCT01763866 · Phase 3
2.7%Q2W
NCT01763866 · Phase 3
1.7%QM
NCT01763866 · Phase 3
3.9%Q2W
NCT01763827 · Phase 3
1.3%QM
NCT01763827 · Phase 3
9%Q2W
NCT01763918 · Phase 3
1.8%QM
NCT01763918 · Phase 3
1%420 mg QM
NCT02392559 · Phase 3
—420 mg QM
NCT02392559 · Phase 3
30.2%
NCT01624142 · Phase 2/3
3%420 mg QM
NCT02624869 · Phase 3
2%420 mg QM
NCT02624869 · Phase 3
15.4%420 mg QM
NCT02624869 · Phase 3
38.3%
NCT04608474 · Phase 4 · registry result, not featured evidence
0%HPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
0%NPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
3.3%
NCT03403374 · Phase 4 · registry result, not featured evidence
14.5%
NCT03689946 · Phase 3 · registry result, not featured evidence
16.4%Once Every 2 Weeks (Q2W) or Once a Month (QM)
NCT02867813 · Phase 3 · registry result, not featured evidence
—Evolocumab in Parent Study
NCT02867813 · Phase 3 · registry result, not featured evidence
3.7%
NCT03570697 · Phase 3 · registry result, not featured evidence
—
NCT02833844 · Phase 3 · registry result, not featured evidence
2.6%Evolocumab + Standard of Care
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Year 1: Evolocumab + Standard of C
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Years 2-3: Evolocumab + SOC / Evol
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Years 2-3: SOC / Evolocumab + SOC
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Q2W
NCT02634580 · Phase 3 · registry result, not featured evidence
—QM
NCT02634580 · Phase 3 · registry result, not featured evidence
1.5%420 mg QM
NCT02729025 · Phase 3 · registry result, not featured evidence
3.2%
NCT02304484 · Phase 3 · registry result, not featured evidence
1.8%Q2W
NCT02662569 · Phase 3 · registry result, not featured evidence
1.2%QM
NCT02662569 · Phase 3 · registry result, not featured evidence
4.8%
NCT01984424 · Phase 3 · registry result, not featured evidence
0.7%
NCT02739984 · Phase 3 · registry result, not featured evidence
3.3%
NCT01813422 · Phase 3 · registry result, not featured evidence
13%Evolocumab
NCT02189837 · Phase 3 · registry result, not featured evidence
9.5%Evolocumab and Atorvastatin
NCT02189837 · Phase 3 · registry result, not featured evidence · combination
0%Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
0%QM
NCT01953328 · Phase 3 · registry result, not featured evidence
0%Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
0%QM
NCT01953328 · Phase 3 · registry result, not featured evidence
8.7%Q2W
NCT01763905 · Phase 3 · registry result, not featured evidence
1%QM
NCT01763905 · Phase 3 · registry result, not featured evidence
6.1%Evolocumab AI/Pen
NCT01879319 · Phase 3 · registry result, not featured evidence
2.4%Evolocumab AMD
NCT01879319 · Phase 3 · registry result, not featured evidence
5.4%Evolocumab AI/Pen
NCT01849497 · Phase 3 · registry result, not featured evidence
1.3%Evolocumab PFS
NCT01849497 · Phase 3 · registry result, not featured evidence
—All-IP Period: Evolocumab + SOC /
NCT01439880 · Phase 2 · registry result, not featured evidence
—All-IP Period: SOC / Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence
6.8%Evolocumab + SOC
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
—SOC-controlled Period: Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
2.9%s
NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 46 more results
—Part 1 - Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2.2%Part 1- Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—Part 1 - Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
0%Part 1- Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 2 - Inclisiran (Total)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
4.7%
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
7.7%
NCT03399370 · Phase 3
2%
NCT05192941 · Phase 4 · registry result, not featured evidence
2.9%Inclisiran - Inclisiran
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran - Inclisiran: Core Part
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran - Inclisiran: Extension
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran + Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
9%Inclisiran With Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
5.7%
NCT05763875 · Phase 3 · registry result, not featured evidence
5.8%
NCT04929249 · Phase 3 · registry result, not featured evidence
100%ORION-3 Rollover
NCT03814187 · Phase 3 · registry result, not featured evidence
17.6%Phase III Inclisiran-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
18.8%Phase III Placebo-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
16.8%Inclisiran
NCT04807400 · Phase 3 · registry result, not featured evidence
15.2%Inclisiran + BS
NCT04807400 · Phase 3 · registry result, not featured evidence · combination
8.1%Part 1 - Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 1: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 2 - Inclisiran-Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 2: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
4%300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
1%200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—Inclisiran Only Arm
NCT03060577 · Phase 2 · registry result, not featured evidence
19.7%Inclisiran-only
NCT03060577 · Phase 2 · registry result, not featured evidence
—Switching Arm After Day 360 Visit
NCT03060577 · Phase 2 · registry result, not featured evidence
55.6%
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
—300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
6.6%300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
4.8%300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
12.1%500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
6.3%200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
1.7%200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
8.1%100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—r
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 64 more results
—Part A: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part A: OL Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: DB Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—
NCT01764633 · Phase 3
—
NCT02207634 · Phase 3
—Q2W
NCT01763866 · Phase 3
—QM
NCT01763866 · Phase 3
—Q2W
NCT01763866 · Phase 3
—QM
NCT01763866 · Phase 3
—Q2W
NCT01763866 · Phase 3
—QM
NCT01763866 · Phase 3
—Q2W
NCT01763866 · Phase 3
—QM
NCT01763866 · Phase 3
—Q2W
NCT01763866 · Phase 3
—QM
NCT01763866 · Phase 3
—Q2W
NCT01763827 · Phase 3
—QM
NCT01763827 · Phase 3
—Q2W
NCT01763918 · Phase 3
—QM
NCT01763918 · Phase 3
—420 mg QM
NCT02392559 · Phase 3
—420 mg QM
NCT02392559 · Phase 3
—
NCT01624142 · Phase 2/3
—420 mg QM
NCT02624869 · Phase 3
—420 mg QM
NCT02624869 · Phase 3
—420 mg QM
NCT02624869 · Phase 3
6.2%
NCT04608474 · Phase 4 · registry result, not featured evidence
—HPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
—NPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
—
NCT03403374 · Phase 4 · registry result, not featured evidence
—
NCT03689946 · Phase 3 · registry result, not featured evidence
—Once Every 2 Weeks (Q2W) or Once a Month (QM)
NCT02867813 · Phase 3 · registry result, not featured evidence
—Evolocumab in Parent Study
NCT02867813 · Phase 3 · registry result, not featured evidence
—
NCT03570697 · Phase 3 · registry result, not featured evidence
—
NCT02833844 · Phase 3 · registry result, not featured evidence
—Evolocumab + Standard of Care
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Year 1: Evolocumab + Standard of C
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Years 2-3: Evolocumab + SOC / Evol
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Years 2-3: SOC / Evolocumab + SOC
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Q2W
NCT02634580 · Phase 3 · registry result, not featured evidence
—QM
NCT02634580 · Phase 3 · registry result, not featured evidence
—420 mg QM
NCT02729025 · Phase 3 · registry result, not featured evidence
—
NCT02304484 · Phase 3 · registry result, not featured evidence
—Q2W
NCT02662569 · Phase 3 · registry result, not featured evidence
—QM
NCT02662569 · Phase 3 · registry result, not featured evidence
—
NCT01984424 · Phase 3 · registry result, not featured evidence
—
NCT02739984 · Phase 3 · registry result, not featured evidence
—
NCT01813422 · Phase 3 · registry result, not featured evidence
—Evolocumab
NCT02189837 · Phase 3 · registry result, not featured evidence
—Evolocumab and Atorvastatin
NCT02189837 · Phase 3 · registry result, not featured evidence · combination
—Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
—QM
NCT01953328 · Phase 3 · registry result, not featured evidence
—Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
—QM
NCT01953328 · Phase 3 · registry result, not featured evidence
—Q2W
NCT01763905 · Phase 3 · registry result, not featured evidence
—QM
NCT01763905 · Phase 3 · registry result, not featured evidence
—Evolocumab AI/Pen
NCT01879319 · Phase 3 · registry result, not featured evidence
—Evolocumab AMD
NCT01879319 · Phase 3 · registry result, not featured evidence
—Evolocumab AI/Pen
NCT01849497 · Phase 3 · registry result, not featured evidence
—Evolocumab PFS
NCT01849497 · Phase 3 · registry result, not featured evidence
—All-IP Period: Evolocumab + SOC /
NCT01439880 · Phase 2 · registry result, not featured evidence
—All-IP Period: SOC / Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence
—Evolocumab + SOC
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
—SOC-controlled Period: Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
—s
NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 46 more results
—Part 1 - Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—Part 1- Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—Part 1 - Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 1- Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 2 - Inclisiran (Total)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—
NCT03399370 · Phase 3
0.3%
NCT05192941 · Phase 4 · registry result, not featured evidence
—Inclisiran - Inclisiran
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran - Inclisiran: Core Part
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran - Inclisiran: Extension
NCT05888103 · Phase 3 · registry result, not featured evidence
—Inclisiran + Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
0%Inclisiran With Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
0.6%
NCT05763875 · Phase 3 · registry result, not featured evidence
0.9%
NCT04929249 · Phase 3 · registry result, not featured evidence
0%ORION-3 Rollover
NCT03814187 · Phase 3 · registry result, not featured evidence
1.5%Phase III Inclisiran-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
1.6%Phase III Placebo-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
0.7%Inclisiran
NCT04807400 · Phase 3 · registry result, not featured evidence
1%Inclisiran + BS
NCT04807400 · Phase 3 · registry result, not featured evidence · combination
—Part 1 - Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 1: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 2 - Inclisiran-Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 2: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—Inclisiran Only Arm
NCT03060577 · Phase 2 · registry result, not featured evidence
3.1%Inclisiran-only
NCT03060577 · Phase 2 · registry result, not featured evidence
—Switching Arm After Day 360 Visit
NCT03060577 · Phase 2 · registry result, not featured evidence
—
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
—300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
Serious AEs
5.5%r
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 64 more results
—Part A: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
0%Part A: OL Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
0%Part B: DB Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
24.8%
NCT01764633 · Phase 3
21.6%
NCT02207634 · Phase 3
3.6%Q2W
NCT01763866 · Phase 3
1.8%QM
NCT01763866 · Phase 3
2.8%Q2W
NCT01763866 · Phase 3
0.9%QM
NCT01763866 · Phase 3
0.9%Q2W
NCT01763866 · Phase 3
2.7%QM
NCT01763866 · Phase 3
2.7%Q2W
NCT01763866 · Phase 3
2.6%QM
NCT01763866 · Phase 3
1.8%Q2W
NCT01763866 · Phase 3
0.9%QM
NCT01763866 · Phase 3
2%Q2W
NCT01763827 · Phase 3
0.7%QM
NCT01763827 · Phase 3
2.7%Q2W
NCT01763918 · Phase 3
3.6%QM
NCT01763918 · Phase 3
—420 mg QM
NCT02392559 · Phase 3
1%420 mg QM
NCT02392559 · Phase 3
27.4%
NCT01624142 · Phase 2/3
2%420 mg QM
NCT02624869 · Phase 3
4.1%420 mg QM
NCT02624869 · Phase 3
16.7%420 mg QM
NCT02624869 · Phase 3
0%
NCT04608474 · Phase 4 · registry result, not featured evidence
5.3%HPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
4.5%NPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
6.7%
NCT03403374 · Phase 4 · registry result, not featured evidence
0%
NCT03689946 · Phase 3 · registry result, not featured evidence
—Once Every 2 Weeks (Q2W) or Once a Month (QM)
NCT02867813 · Phase 3 · registry result, not featured evidence
41.8%Evolocumab in Parent Study
NCT02867813 · Phase 3 · registry result, not featured evidence
16.3%
NCT03570697 · Phase 3 · registry result, not featured evidence
3.3%
NCT02833844 · Phase 3 · registry result, not featured evidence
—Evolocumab + Standard of Care
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
7.9%Year 1: Evolocumab + Standard of C
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
14.4%Years 2-3: Evolocumab + SOC / Evol
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
15.1%Years 2-3: SOC / Evolocumab + SOC
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
0%Q2W
NCT02634580 · Phase 3 · registry result, not featured evidence
0%QM
NCT02634580 · Phase 3 · registry result, not featured evidence
3.1%420 mg QM
NCT02729025 · Phase 3 · registry result, not featured evidence
19.9%
NCT02304484 · Phase 3 · registry result, not featured evidence
3.1%Q2W
NCT02662569 · Phase 3 · registry result, not featured evidence
6.6%QM
NCT02662569 · Phase 3 · registry result, not featured evidence
6.2%
NCT01984424 · Phase 3 · registry result, not featured evidence
5%
NCT02739984 · Phase 3 · registry result, not featured evidence
27.9%
NCT01813422 · Phase 3 · registry result, not featured evidence
0%Evolocumab
NCT02189837 · Phase 3 · registry result, not featured evidence
5%Evolocumab and Atorvastatin
NCT02189837 · Phase 3 · registry result, not featured evidence · combination
0%Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
0%QM
NCT01953328 · Phase 3 · registry result, not featured evidence
0%Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
2%QM
NCT01953328 · Phase 3 · registry result, not featured evidence
4.9%Q2W
NCT01763905 · Phase 3 · registry result, not featured evidence
1%QM
NCT01763905 · Phase 3 · registry result, not featured evidence
1.2%Evolocumab AI/Pen
NCT01879319 · Phase 3 · registry result, not featured evidence
0%Evolocumab AMD
NCT01879319 · Phase 3 · registry result, not featured evidence
2.7%Evolocumab AI/Pen
NCT01849497 · Phase 3 · registry result, not featured evidence
4%Evolocumab PFS
NCT01849497 · Phase 3 · registry result, not featured evidence
22%All-IP Period: Evolocumab + SOC /
NCT01439880 · Phase 2 · registry result, not featured evidence
19.6%All-IP Period: SOC / Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence
—Evolocumab + SOC
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
8.2%SOC-controlled Period: Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
7.5%s
NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 46 more results
3.2%Part 1 - Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
—Part 1- Inclisiran
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
0%Part 1 - Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 1- Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
0%Part 2 - Inclisiran (Total)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
22.3%
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
22.4%
NCT03399370 · Phase 3
16.4%
NCT05192941 · Phase 4 · registry result, not featured evidence
—Inclisiran - Inclisiran
NCT05888103 · Phase 3 · registry result, not featured evidence
4.9%Inclisiran - Inclisiran: Core Part
NCT05888103 · Phase 3 · registry result, not featured evidence
1%Inclisiran - Inclisiran: Extension
NCT05888103 · Phase 3 · registry result, not featured evidence
15.8%Inclisiran + Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
—Inclisiran With Usual Care
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
0.6%
NCT05763875 · Phase 3 · registry result, not featured evidence
11.5%
NCT04929249 · Phase 3 · registry result, not featured evidence
15.1%ORION-3 Rollover
NCT03814187 · Phase 3 · registry result, not featured evidence
30.7%Phase III Inclisiran-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
32.6%Phase III Placebo-Inclisiran
NCT03814187 · Phase 3 · registry result, not featured evidence
8.8%Inclisiran
NCT04807400 · Phase 3 · registry result, not featured evidence
12.8%Inclisiran + BS
NCT04807400 · Phase 3 · registry result, not featured evidence · combination
—Part 1 - Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
5.4%Part 1: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—Part 2 - Inclisiran-Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
20.8%Part 2: Inclisiran
NCT03851705 · Phase 3 · registry result, not featured evidence
—300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
7.1%300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
6.9%200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
—100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
3.6%100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
36.6%Inclisiran Only Arm
NCT03060577 · Phase 2 · registry result, not featured evidence
—Inclisiran-only
NCT03060577 · Phase 2 · registry result, not featured evidence
34.5%Switching Arm After Day 360 Visit
NCT03060577 · Phase 2 · registry result, not featured evidence
25%
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
14.8%300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
18%300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—300 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
12.3%500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—500 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
12.9%200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
18.3%200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—200 mg single dose
NCT02597127 · Phase 2 · registry result, not featured evidence
21.3%100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
—100 mg double dose
NCT02597127 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
r
nasopharyngitis 10.5% (placebo 9.6%)
upper respiratory tract infection 9.3% (placebo 6.3%)
influenza 7.5% (placebo 6.3%)
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 54 more results
bronchitis 12.5% (placebo 0%)
dyspepsia 12.5% (placebo 0%)
pain 12.5% (placebo 0%)
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
influenza 9.1% (placebo 0%)
upper respiratory tract infection 9.1% (placebo 6.3%)
gastroenteritis 6.1% (placebo 0%)
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
diabetes mellitus 8.4% (placebo 8%)
hypertension 7.8% (placebo 8.4%)
nasopharyngitis 7.7% (placebo 7.4%)
NCT01764633 · Phase 3
nasopharyngitis 10.3% (placebo 7.5%)
hypertension 6.2% (placebo 6.7%)
back pain 5.9% (placebo 3.6%)
NCT02207634 · Phase 3
Q2W
muscle spasms 2.7% (placebo 0%)
back pain 1.8% (placebo 0%)
diarrhoea 1.8% (placebo 0%)
NCT01763866 · Phase 3
QM
muscle spasms 3.6% (placebo 0%)
back pain 0.9% (placebo 0%)
dizziness 0.9% (placebo 0%)
NCT01763866 · Phase 3
Q2W
diarrhoea 3.7% (placebo 0%)
back pain 2.8% (placebo 0%)
muscle spasms 1.8% (placebo 0%)
NCT01763866 · Phase 3
QM
headache 2.7% (placebo 1.8%)
diarrhoea 1.8% (placebo 0%)
myalgia 1.8% (placebo 3.6%)
NCT01763866 · Phase 3
Q2W
back pain 1.8% (placebo 0%)
headache 1.8% (placebo 1.8%)
myalgia 0.9% (placebo 3.6%)
NCT01763866 · Phase 3
QM
headache 2.7% (placebo 1.8%)
back pain 0.9% (placebo 0%)
diarrhoea 0.9% (placebo 0%)
NCT01763866 · Phase 3
Q2W
muscle spasms 1.8% (placebo 0%)
back pain 0.9% (placebo 0%)
constipation 0.9% (placebo 5.4%)
NCT01763866 · Phase 3
QM
back pain 1.7% (placebo 0%)
diarrhoea 1.7% (placebo 0%)
dizziness 1.7% (placebo 0%)
NCT01763866 · Phase 3
Q2W
back pain 5.4% (placebo 0%)
dizziness 2.7% (placebo 0%)
muscle spasms 2.7% (placebo 0%)
NCT01763866 · Phase 3
QM
headache 4.3% (placebo 1.8%)
myalgia 2.6% (placebo 3.6%)
back pain 1.7% (placebo 0%)
NCT01763866 · Phase 3
Q2W
headache 3.3% (placebo 3.9%)
diarrhoea 2.6% (placebo 6.6%)
nasopharyngitis 2% (placebo 1.3%)
NCT01763827 · Phase 3
QM
diarrhoea 3.3% (placebo 6.6%)
headache 3.3% (placebo 3.9%)
nasopharyngitis 2% (placebo 1.3%)
NCT01763827 · Phase 3
Q2W
nasopharyngitis 7.3% (placebo 3.7%)
arthralgia 6.4% (placebo 1.9%)
headache 3.6% (placebo 1.9%)
NCT01763918 · Phase 3
QM
nasopharyngitis 10% (placebo 3.7%)
back pain 5.5% (placebo 0%)
headache 4.5% (placebo 1.9%)
NCT01763918 · Phase 3
420 mg QM
nasopharyngitis 11.5% (placebo 11.3%)
headache 10.6% (placebo 1.9%)
oropharyngeal pain 6.7% (placebo 0%)
NCT02392559 · Phase 3
upper respiratory tract infection 17%
headache 16%
influenza 16%
NCT01624142 · Phase 2/3
420 mg QM
nasopharyngitis 13.9%
headache 8.9%
influenza like illness 7.9%
NCT02624869 · Phase 3
420 mg QM
nasopharyngitis 16.3%
influenza like illness 10.2%
pyrexia 10.2%
NCT02624869 · Phase 3
420 mg QM
epistaxis 16.7%
abdominal pain upper 8.3%
acne 8.3%
NCT02624869 · Phase 3
allergic skin reaction 4.5%
elevated creatine kinase 1.5%
NCT04608474 · Phase 4 · registry result, not featured evidence
angina pectoris 3.3%
arthralgia 3.3%
arthritis 3.3%
NCT03403374 · Phase 4 · registry result, not featured evidence
runny nose 5.5%
NCT03689946 · Phase 3 · registry result, not featured evidence
hypertension 14.2% (placebo 12.9%)
bronchitis 6.9% (placebo 6.4%)
upper respiratory tract infection 6.5% (placebo 8.2%)
NCT02867813 · Phase 3 · registry result, not featured evidence
hypertension 7.5% (placebo 6.2%)
myalgia 6.3% (placebo 7.4%)
angina pectoris 5% (placebo 8.6%)
NCT03570697 · Phase 3 · registry result, not featured evidence
back pain 3.9% (placebo 2.5%)
influenza like illness 3.9% (placebo 2.5%)
diarrhoea 3.6% (placebo 4.5%)
NCT02833844 · Phase 3 · registry result, not featured evidence
nasopharyngitis 8.2%
arthralgia 4.3%
upper respiratory tract infection 4.2%
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 10.6%
hypertension 7.5%
upper respiratory tract infection 7.4%
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 12.6%
upper respiratory tract infection 8.3%
arthralgia 6.7%
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
Q2W
pharyngitis 15.8%
abdominal distension 10.5%
abdominal pain 5.3%
NCT02634580 · Phase 3 · registry result, not featured evidence
QM
nasopharyngitis 23.8%
hypertension 9.5%
injection site pain 9.5%
NCT02634580 · Phase 3 · registry result, not featured evidence
420 mg QM
influenza 10.8% (placebo 4.7%)
nasopharyngitis 9.2% (placebo 20.3%)
myalgia 7.7% (placebo 1.6%)
NCT02729025 · Phase 3 · registry result, not featured evidence
hypertension 6.4%
NCT02304484 · Phase 3 · registry result, not featured evidence
Q2W
diabetes mellitus 4.6% (placebo 1.2%)
nasopharyngitis 2.8% (placebo 3.7%)
upper respiratory tract infection 2.8% (placebo 3.7%)
NCT02662569 · Phase 3 · registry result, not featured evidence
QM
diabetes mellitus 4.5% (placebo 1.2%)
upper respiratory tract infection 3.9% (placebo 3.7%)
nasopharyngitis 3.3% (placebo 3.7%)
NCT02662569 · Phase 3 · registry result, not featured evidence
myalgia 13.8%
nasopharyngitis 9.7%
arthralgia 9%
NCT01984424 · Phase 3 · registry result, not featured evidence
hypertension 3.9% (placebo 0%)
diabetes mellitus 2.9% (placebo 3.5%)
diarrhoea 2.1% (placebo 2.8%)
NCT02739984 · Phase 3 · registry result, not featured evidence
myalgia 7% (placebo 5.6%)
chest pain 6.8% (placebo 5.4%)
hypertension 6% (placebo 7%)
NCT01813422 · Phase 3 · registry result, not featured evidence
headache 36.4% (placebo 9.5%)
influenza like illness 9.1% (placebo 0%)
nasopharyngitis 9.1% (placebo 4.8%)
NCT02189837 · Phase 3 · registry result, not featured evidence
headache 35% (placebo 9.5%)
myalgia 10% (placebo 4.8%)
nausea 10% (placebo 4.8%)
NCT02189837 · Phase 3 · registry result, not featured evidence · combination
Q2W
nasopharyngitis 13.7% (placebo 9.6%)
diabetes mellitus 2% (placebo 0%)
gastroenteritis 0% (placebo 1.9%)
NCT01953328 · Phase 3 · registry result, not featured evidence
QM
nasopharyngitis 15.7% (placebo 9.6%)
gastroenteritis 5.9% (placebo 1.9%)
diabetes mellitus 3.9% (placebo 0%)
NCT01953328 · Phase 3 · registry result, not featured evidence
Q2W
nasopharyngitis 24% (placebo 9.6%)
diabetes mellitus 2% (placebo 0%)
gastroenteritis 2% (placebo 1.9%)
NCT01953328 · Phase 3 · registry result, not featured evidence
QM
nasopharyngitis 14% (placebo 9.6%)
gastroenteritis 4% (placebo 1.9%)
diabetes mellitus 0% (placebo 0%)
NCT01953328 · Phase 3 · registry result, not featured evidence
Q2W
myalgia 6.8%
muscle spasms 4.9%
nasopharyngitis 4.9%
NCT01763905 · Phase 3 · registry result, not featured evidence
QM
headache 11.8%
pain in extremity 11.8%
myalgia 8.8%
NCT01763905 · Phase 3 · registry result, not featured evidence
headache 2.7%
NCT01849497 · Phase 3 · registry result, not featured evidence
headache 5.3%
NCT01849497 · Phase 3 · registry result, not featured evidence
nasopharyngitis 28.7%
upper respiratory tract infection 14.4%
back pain 14.2%
NCT01439880 · Phase 2 · registry result, not featured evidence
nasopharyngitis 30.7%
arthralgia 15.8%
upper respiratory tract infection 14.3%
NCT01439880 · Phase 2 · registry result, not featured evidence
nasopharyngitis 16.8%
upper respiratory tract infection 8.2%
back pain 7%
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
s
nasopharyngitis 11.6% (placebo 8.3%)
injection site reaction 9.1% (placebo 0%)
back pain 7.1% (placebo 4.2%)
NCT03397121 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 30 more results
covid-19 18.3% (placebo 25%)
nasopharyngitis 14% (placebo 18.8%)
headache 12.9% (placebo 6.3%)
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
covid-19 44.4% (placebo 25%)
abdominal pain upper 22.2% (placebo 0%)
injection site reaction 22.2% (placebo 0%)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
headache 15.4% (placebo 0%)
influenza 15.4% (placebo 0%)
abdominal pain upper 7.7% (placebo 0%)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
nasopharyngitis 11.2% (placebo 11.2%)
diabetes mellitus 10.9% (placebo 11.7%)
hypertension 6.5% (placebo 6.7%)
NCT03400800 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
diabetes mellitus 15.4% (placebo 13.9%)
bronchitis 5.9% (placebo 3.9%)
hypertension 5.4% (placebo 5.4%)
NCT03399370 · Phase 3
nasopharyngitis 8.2% (placebo 9.1%)
covid-19 6.1% (placebo 6.3%)
diabetes mellitus inadequate control 6.1% (placebo 5.6%)
NCT05192941 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 24.3% (placebo 16.3%)
blood glucose increased 9.7% (placebo 6.7%)
blood creatine phosphokinase increased 6.8% (placebo 5.8%)
NCT05888103 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 14% (placebo 16.3%)
blood creatine phosphokinase increased 6% (placebo 5.8%)
alanine aminotransferase increased 5% (placebo 2.9%)
NCT05888103 · Phase 3 · registry result, not featured evidence
covid-19 4.9%
injection site pain 4.9%
arthralgia 3.9%
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
headache 3.4% (placebo 0%)
nasopharyngitis 3.4% (placebo 3.4%)
urinary tract infection 1.7% (placebo 2.3%)
NCT05763875 · Phase 3 · registry result, not featured evidence
covid-19 7.7%
injection site pain 7.7%
blood creatine phosphokinase increased 4.3%
NCT04929249 · Phase 3 · registry result, not featured evidence
covid-19 18.3%
urinary tract infection 3.5%
hypertension 3.2%
NCT03814187 · Phase 3 · registry result, not featured evidence
covid-19 11.8%
diabetes mellitus inadequate control 7.5%
hypertension 7%
NCT03814187 · Phase 3 · registry result, not featured evidence
covid-19 11.9%
diabetes mellitus inadequate control 7.4%
hypertension 7.4%
NCT03814187 · Phase 3 · registry result, not featured evidence
back pain 0.4%
injection site rash 0.4%
muscle spasms 0.4%
NCT04807400 · Phase 3 · registry result, not featured evidence
dizziness 0.4%
rash 0.4%
back pain 0%
NCT04807400 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 5.4% (placebo 0%)
pyrexia 5.4% (placebo 0%)
respiratory tract infection viral 5.4% (placebo 10.5%)
NCT03851705 · Phase 3 · registry result, not featured evidence
corona virus infection 7.5% (placebo 0%)
international normalised ratio increased 5.7% (placebo 0%)
activated partial thromboplastin time prolonged 3.8% (placebo 0%)
NCT03851705 · Phase 3 · registry result, not featured evidence
300 mg
pyrexia 18.2% (placebo 12.3%)
diabetes mellitus inadequate control 15.2% (placebo 15.8%)
diabetes mellitus 12.1% (placebo 8.8%)
NCT04666298 · Phase 2 · registry result, not featured evidence
200 mg
diabetes mellitus 11.9% (placebo 8.8%)
injection site reaction 11.9% (placebo 3.5%)
pyrexia 11.9% (placebo 12.3%)
NCT04666298 · Phase 2 · registry result, not featured evidence
100 mg
diabetes mellitus 20% (placebo 8.8%)
covid-19 14.5% (placebo 3.5%)
pyrexia 14.5% (placebo 12.3%)
NCT04666298 · Phase 2 · registry result, not featured evidence
nasopharyngitis 19.4% (placebo 6.7%)
hypertension 14.8% (placebo 2.2%)
arthralgia 14.1% (placebo 11.1%)
NCT03060577 · Phase 2 · registry result, not featured evidence
hypertension 19.5% (placebo 2.2%)
back pain 14.9% (placebo 1.1%)
nasopharyngitis 14.9% (placebo 6.7%)
NCT03060577 · Phase 2 · registry result, not featured evidence
abdominal pain upper 25%
acne 25%
angina unstable 25%
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
300 mg double dose
nasopharyngitis 18% (placebo 12.9%)
musculoskeletal pain 9.8% (placebo 6.5%)
diarrhoea 8.2% (placebo 3.2%)
NCT02597127 · Phase 2 · registry result, not featured evidence
300 mg single dose
nasopharyngitis 14.8% (placebo 12.9%)
cough 11.5% (placebo 4.8%)
myalgia 9.8% (placebo 4.8%)
NCT02597127 · Phase 2 · registry result, not featured evidence
500 mg single dose
nasopharyngitis 13.8% (placebo 12.9%)
influenza 7.7% (placebo 3.2%)
upper respiratory tract infection 7.7% (placebo 3.2%)
NCT02597127 · Phase 2 · registry result, not featured evidence
200 mg double dose
diarrhoea 11.3% (placebo 3.2%)
cough 9.7% (placebo 4.8%)
arthralgia 8.1% (placebo 1.6%)
NCT02597127 · Phase 2 · registry result, not featured evidence
200 mg single dose
nasopharyngitis 13.3% (placebo 12.9%)
arthralgia 6.7% (placebo 1.6%)
back pain 6.7% (placebo 3.2%)
NCT02597127 · Phase 2 · registry result, not featured evidence
100 mg double dose
nasopharyngitis 13.1% (placebo 12.9%)
myalgia 11.5% (placebo 4.8%)
back pain 9.8% (placebo 3.2%)
NCT02597127 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2/3 versus Phase 2.
  2. bPopulation context differs: registered conditions differ.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 216 weeks versus 205.71 weeks.
  5. ePopulation context differs: baseline_threshold differs (ldl_c>=75 versus ldl_c>130).
  6. fTreatment context differs: combination versus monotherapy.
  7. gAssessment timepoints differ: 52 weeks versus 51.43 weeks.
  8. hPopulation context differs: baseline_threshold differs (ldl_c>=75 versus ldl_c>=70); comorbidity_cardiovascular_disease differs (none recorded versus required); prior_therapy differs (experienced versus none recorded).
  9. iThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  10. jTrial phases differ: Phase 3 versus Phase 2.
  11. kAssessment timepoints differ: 80 weeks versus 205.71 weeks.
  12. lAssessment timepoints differ: 104 weeks versus 47.14 weeks.
  13. mPopulation comparability has not been reviewed for both studies.
  14. nThe assessment timepoint is not available for both results.
  15. oTrial phases differ: Phase 2/3 versus Phase 3.
  16. pAssessment timepoints differ: 216 weeks versus 102.86 weeks.
  17. qAssessment timepoints differ: 52 weeks versus 72.9 weeks.
  18. rPopulation comparability has not been reviewed for 60 of these studies.
  19. sPopulation comparability has not been reviewed for 40 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Evolocumab

LDL-C 82.3% (n=599) vs 6.4% (n=302) placebo @ 52wk
responder rate · % of participants
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
MACE Composite 2.74% (n=13784) vs 3.11% (n=13780) placebo @ 26wk
responder rate · % of participants
NCT01764633 · Phase 3
show 5 more results
5.31% (n=13784) vs 6.01% (n=13780) placebo @ 52wk
NCT01764633 · Phase 3
7.25% (n=13784) vs 8.32% (n=13780) placebo @ 78wk
NCT01764633 · Phase 3
9.13% (n=13784) vs 10.66% (n=13780) placebo @ 104wk
NCT01764633 · Phase 3
10.91% (n=13784) vs 12.72% (n=13780) placebo @ 130wk
NCT01764633 · Phase 3
12.57% (n=13784) vs 14.64% (n=13780) placebo @ 156wk
NCT01764633 · Phase 3
MACE 3-point Composite 1.65% (n=13784) vs 1.86% (n=13780) placebo @ 26wk
event count · % of participants
NCT01764633 · Phase 3
show 5 more results
3.1% (n=13784) vs 3.68% (n=13780) placebo @ 52wk
NCT01764633 · Phase 3
4.29% (n=13784) vs 5.18% (n=13780) placebo @ 78wk
NCT01764633 · Phase 3
5.47% (n=13784) vs 6.83% (n=13780) placebo @ 104wk
NCT01764633 · Phase 3
6.66% (n=13784) vs 8.31% (n=13780) placebo @ 130wk
NCT01764633 · Phase 3
7.9% (n=13784) vs 9.93% (n=13780) placebo @ 156wk
NCT01764633 · Phase 3
CV Death 0.39% (n=13784) vs 0.4% (n=13780) placebo @ 26wk
responder rate · % of participants
NCT01764633 · Phase 3
show 5 more results
0.79% (n=13784) vs 0.82% (n=13780) placebo @ 52wk
NCT01764633 · Phase 3
1.2% (n=13784) vs 1.19% (n=13780) placebo @ 78wk
NCT01764633 · Phase 3
1.64% (n=13784) vs 1.57% (n=13780) placebo @ 104wk
NCT01764633 · Phase 3
2.11% (n=13784) vs 1.99% (n=13780) placebo @ 130wk
NCT01764633 · Phase 3
2.49% (n=13784) vs 2.39% (n=13780) placebo @ 156wk
NCT01764633 · Phase 3
All-cause Mortality 0.55% (n=13784) vs 0.62% (n=13780) placebo @ 26wk
responder rate · % of participants
NCT01764633 · Phase 3
show 5 more results
1.26% (n=13784) vs 1.29% (n=13780) placebo @ 52wk
NCT01764633 · Phase 3
1.94% (n=13784) vs 1.96% (n=13780) placebo @ 78wk
NCT01764633 · Phase 3
2.81% (n=13784) vs 2.78% (n=13780) placebo @ 104wk
NCT01764633 · Phase 3
3.63% (n=13784) vs 3.48% (n=13780) placebo @ 130wk
NCT01764633 · Phase 3
4.75% (n=13784) vs 4.28% (n=13780) placebo @ 156wk
NCT01764633 · Phase 3
MI 1.06% (n=13784) vs 1.14% (n=13780) placebo @ 26wk
responder rate · % of participants
NCT01764633 · Phase 3
show 5 more results
1.9% (n=13784) vs 2.39% (n=13780) placebo @ 52wk
NCT01764633 · Phase 3
2.55% (n=13784) vs 3.33% (n=13780) placebo @ 78wk
NCT01764633 · Phase 3
3.21% (n=13784) vs 4.3% (n=13780) placebo @ 104wk
NCT01764633 · Phase 3
3.83% (n=13784) vs 5.25% (n=13780) placebo @ 130wk
NCT01764633 · Phase 3
4.41% (n=13784) vs 6.28% (n=13780) placebo @ 156wk
NCT01764633 · Phase 3
Stroke 0.31% (n=13784) vs 0.5% (n=13780) placebo @ 26wk
responder rate · % of participants
NCT01764633 · Phase 3
show 11 more results
0.7% (n=13784) vs 0.85% (n=13780) placebo @ 52wk
NCT01764633 · Phase 3
1.05% (n=13784) vs 1.3% (n=13780) placebo @ 78wk
NCT01764633 · Phase 3
1.36% (n=13784) vs 1.8% (n=13780) placebo @ 104wk
NCT01764633 · Phase 3
1.71% (n=13784) vs 2.15% (n=13780) placebo @ 130wk
NCT01764633 · Phase 3
2.18% (n=13784) vs 2.6% (n=13780) placebo @ 156wk
NCT01764633 · Phase 3
0.42% (n=13784) vs 0.61% (n=13780) placebo @ 26wk
NCT01764633 · Phase 3
0.83% (n=13784) vs 1.05% (n=13780) placebo @ 52wk
NCT01764633 · Phase 3
1.18% (n=13784) vs 1.52% (n=13780) placebo @ 78wk
NCT01764633 · Phase 3
1.46% (n=13784) vs 2.05% (n=13780) placebo @ 104wk
NCT01764633 · Phase 3
1.92% (n=13784) vs 2.4% (n=13780) placebo @ 130wk
NCT01764633 · Phase 3
2.48% (n=13784) vs 2.81% (n=13780) placebo @ 156wk
NCT01764633 · Phase 3
Coronary Revascularization 1.6% (n=13784) vs 1.87% (n=13780) placebo @ 26wk
responder rate · % of participants
NCT01764633 · Phase 3
show 5 more results
3.13% (n=13784) vs 3.71% (n=13780) placebo @ 52wk
NCT01764633 · Phase 3
4.16% (n=13784) vs 5.2% (n=13780) placebo @ 78wk
NCT01764633 · Phase 3
5.22% (n=13784) vs 6.57% (n=13780) placebo @ 104wk
NCT01764633 · Phase 3
6.13% (n=13784) vs 7.91% (n=13780) placebo @ 130wk
NCT01764633 · Phase 3
7.01% (n=13784) vs 9.17% (n=13780) placebo @ 156wk
NCT01764633 · Phase 3
CV Death or HF Hospitalization Composite 0.64% (n=13784) vs 0.79% (n=13780) placebo @ 26wk
responder rate · % of participants
NCT01764633 · Phase 3
show 5 more results
1.29% (n=13784) vs 1.35% (n=13780) placebo @ 52wk
NCT01764633 · Phase 3
1.99% (n=13784) vs 1.99% (n=13780) placebo @ 78wk
NCT01764633 · Phase 3
2.64% (n=13784) vs 2.7% (n=13780) placebo @ 104wk
NCT01764633 · Phase 3
3.31% (n=13784) vs 3.45% (n=13780) placebo @ 130wk
NCT01764633 · Phase 3
4.13% (n=13784) vs 4.03% (n=13780) placebo @ 156wk
NCT01764633 · Phase 3
CANTAB SWM Strategy 0.1134 vs 0.1206 placebo score
absolute change · score
NCT02207634 · Phase 3
CANTAB SWM Between-errors 0.0691 vs 0.1024 placebo score
absolute change · score
NCT02207634 · Phase 3
CANTAB PAL Total Errors 0.0873 vs 0.1098 placebo score
absolute change · score
NCT02207634 · Phase 3

+ 21 further endpoints in the CSV export.

Inclisiran

Apo B Change mg/dL -33.3 vs 0 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 6 more results
-29.2 vs 2.9 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-26.1 vs -0.6 placebo mg/dL @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-42.64 vs -0.76 placebo mg/dL @ 21.43wk
NCT05888103 · Phase 3 · registry result, not featured evidence
-9.4 vs 10 placebo mg/dL @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-1.4 vs 3.3 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-7.4 vs 8.4 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
Lp a Change -12.5 vs 3.2 placebo nmol/L @ 21.43wk
absolute change · nmol/L
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 6 more results
-9.5 vs 5.3 placebo nmol/L @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-10.2 vs 4.4 placebo nmol/L @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-19.3 vs -5.3 Usual Care nmol/L @ 47wk
NCT04873934 · Phase 3 · registry result, not featured evidence · combination
-3.8 vs 5.8 placebo nmol/L @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-5.6 vs 3.9 placebo nmol/L @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-5.1 vs 1.2 placebo nmol/L @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
Non-HDL-C Change mg/dL -60.2 vs 5.7 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 6 more results
-52.6 vs 0.5 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-49.7 vs -3 placebo mg/dL @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-73.48 vs -1.14 placebo mg/dL @ 21.43wk
NCT05888103 · Phase 3 · registry result, not featured evidence
-15.3 vs 3.8 placebo mg/dL @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
0.6 vs -11.6 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-12.7 vs -5.7 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
Total Cholesterol Change mg/dL -59 vs 6.6 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 6 more results
-49.4 vs -0.9 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-48.2 vs -3.1 placebo mg/dL @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-68.82 vs 2.64 placebo mg/dL @ 21.43wk
NCT05888103 · Phase 3 · registry result, not featured evidence
-15.1 vs 3.9 placebo mg/dL @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
0.6 vs -10.5 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-12.6 vs -6.8 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
Triglycerides 6.9 vs -4.8 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 2 more results
-2.9 vs 3.5 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-3.1 vs -1.7 placebo mg/dL @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
HDL-C Change mg/dL 1.2 vs 0.9 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 6 more results
3.2 vs -1.4 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
1.5 vs -0.1 placebo mg/dL @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
4.66 vs 3.6 placebo mg/dL @ 21.43wk
NCT05888103 · Phase 3 · registry result, not featured evidence
0.2 vs 0 placebo mg/dL @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
0 vs 1 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
0 vs -1.2 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
VLDL-C Change mg/dL 0.7 vs -0.9 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 5 more results
-0.7 vs 0.8 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
-0.7 vs -0.2 placebo mg/dL @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
1.6 vs 0.6 placebo mg/dL @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
0.4 vs 3 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
1.5 vs 1.8 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
Apo A1 3.98% (n=98) vs 0.04% (n=57) placebo @ 2wk300 mg
percent change · % of baseline
NCT04666298 · Phase 2 · registry result, not featured evidence
show 30 more results
4.35% (n=98) vs 0.9% (n=57) placebo @ 4.29wk300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
5.18% (n=98) vs 0% (n=57) placebo @ 8.57wk300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
5.21% (n=98) vs -0.35% (n=57) placebo @ 12.86wk300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
4.99% (n=98) vs 0.14% (n=57) placebo @ 14.86wk300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
6.6% (n=98) vs 1.79% (n=57) placebo @ 17.14wk300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
8.35% (n=98) vs 3.7% (n=57) placebo @ 21.43wk300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
9.09% (n=98) vs 6.09% (n=57) placebo @ 25.71wk300 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
2.29% (n=101) vs 0.04% (n=57) placebo @ 2wk200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
4.52% (n=101) vs 0.9% (n=57) placebo @ 4.29wk200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
3.89% (n=101) vs 0% (n=57) placebo @ 8.57wk200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
5.71% (n=101) vs -0.35% (n=57) placebo @ 12.86wk200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
5.66% (n=101) vs 0.14% (n=57) placebo @ 14.86wk200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
6.49% (n=101) vs 1.79% (n=57) placebo @ 17.14wk200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
7.46% (n=101) vs 3.7% (n=57) placebo @ 21.43wk200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
10.26% (n=101) vs 6.09% (n=57) placebo @ 25.71wk200 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
3.64% (n=55) vs 0.04% (n=57) placebo @ 2wk100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
2.7% (n=55) vs 0.9% (n=57) placebo @ 4.29wk100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
4.71% (n=55) vs 0% (n=57) placebo @ 8.57wk100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
3.86% (n=55) vs -0.35% (n=57) placebo @ 12.86wk100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
5.89% (n=55) vs 0.14% (n=57) placebo @ 14.86wk100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
5.33% (n=55) vs 1.79% (n=57) placebo @ 17.14wk100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
4.85% (n=55) vs 3.7% (n=57) placebo @ 21.43wk100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
4.99% (n=55) vs 6.09% (n=57) placebo @ 25.71wk100 mg
NCT04666298 · Phase 2 · registry result, not featured evidence
3.7% (n=92) vs 0.4% (n=48) placebo @ 21.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
5.2% (n=92) vs -1.5% (n=48) placebo @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
3% (n=92) vs -1.5% (n=48) placebo @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
5.11% (n=103) vs 3.06% (n=104) placebo @ 21.43wk
NCT05888103 · Phase 3 · registry result, not featured evidence
0.6% (n=37) vs 1.6% (n=19) placebo @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
0.4% (n=37) vs 3% (n=19) placebo @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-1% (n=37) vs 1.6% (n=19) placebo @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
Apo-A1 Change mg/dL 3.3 vs 0 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
show 6 more results
6.1 vs -2.8 placebo mg/dL @ 47.14wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
2.7 vs -2.6 placebo mg/dL @ 51.43wk
NCT04652726 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3
6.44 vs 3.31 placebo mg/dL @ 21.43wk
NCT05888103 · Phase 3 · registry result, not featured evidence
0.6 vs 2.6 placebo mg/dL @ 12.86wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-1.4 vs 4 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3 · registry result, not featured evidence
-1.3 vs 1.4 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3 · registry result, not featured evidence
LDL-C Goal Attainment 84.9% (n=886) vs 31% (n=859) placebo @ 12.9wk
event count · % of participants
NCT05192941 · Phase 4 · registry result, not featured evidence · converted to % from 752 Participants as posted
Triglyceride Change mg/dL -15.32 vs -7.36 placebo mg/dL @ 21.43wk
absolute change · mg/dL
NCT05888103 · Phase 3 · registry result, not featured evidence
LDL-C -67.55 mg/dL @ 47.14wk
absolute change · mg/dL
Extension (open-label)
No placebo or comparator arm
NCT05888103 · Phase 3 · registry result, not featured evidence

+ 42 further endpoints in the CSV export.

Homozygous Familial Hypercholesterolemia

Shared mechanism: PCSK9 · full Homozygous Familial Hypercholesterolemia pipeline

Evolocumab · Repatha

Marketed by Amgen

Approved in Homozygous Familial Hypercholesterolemiamonoclonal antibody
Reliable signal

NCT01588496 · Phase 2/3 · completed

The randomized, quadruple-blind, placebo-controlled Part B (n=49) used a hard, regulator-accepted endpoint (LDL-C change from baseline) and the primary comparison was statistically significant and strongly favored evolocumab (LS mean difference -30.93%, 95% CI -43.86 to -18.00, p<0.001). Part A was an open-label single-arm pilot, but the grade is based on the randomized placebo-controlled Part B, which provides strong evidence for the drug.

Reported efficacy

Part A: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline and Week 12); Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline and Week 12): Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12: Evolocumab -23.05% (Standard Error 3.78) vs Placebo 7.88% (Standard Error 5.26); LS mean treatment difference -30.93% (95% CI -43.86 to -18.00), p<0.001 (met)

Result source: NCT01588496

Inclisiran · Leqvio

Marketed by Novartis and partners

Approved in Homozygous Familial HypercholesterolemiaRNAi (siRNA)
Partial signal

NCT04659863 · Phase 3 · completed

The first year was randomized, double-blind, and placebo-controlled, with 9 participants receiving inclisiran and 4 receiving placebo. The primary LDL-C endpoint was met, but the total sample of 13 was very small and underpowered for reliable generalization, so the findings provide limited evidence despite the favorable result.

Next expected readout: March 2028 · NCT06597006 (registry estimate)

Reported efficacy

Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52) (met)

Result source: NCT04659863

Results for Homozygous Familial Hypercholesterolemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Evolocumab: 7 of 8 rows · Inclisiran: 7 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEvolocumabInclisiran
Rows use multiple source trials
Apo B
percent change · % of baseline
-19.17% (n=33) vs 3.97% (n=16) placebo @ 12wka,b,c
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
show 1 more dose
-20.24% (n=33) vs 2.65% (n=16) placebo
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
-14.8% (n=9) vs 10.6% (n=4) placebo @ 51.43wkb,c
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
Apo B
percent change · % of baseline
No placebo or comparator arm
-14.9% (n=8) @ 12wkb,d,e,f,g
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
1 other source trial
-6% (n=29) @ 12wk
NCT03403374 · Phase 4 · registry result, not featured evidence
-8% (n=34) @ 102.86wkb,d,e,f,g
NCT03851705 · Phase 3
1 other source trial
-7.3% (n=13) @ 102.86wk
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
Lp(a
percent change · % of baseline
-9.4% (n=33) vs 2.43% (n=16) placebo @ 12wka,b,c
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
show 1 more dose
-12.71% (n=33) vs -1.43% (n=16) placebo
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
-1.7% (n=9) vs -12.1% (n=4) placebo @ 51.43wkb,c
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
Non-HDL-C
percent change · % of baseline
No placebo or comparator arm
-16.6% (n=8) @ 12wkb,d,e,f,g
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
-5% (n=34) @ 102.86wkb,d,e,f,g
NCT03851705 · Phase 3
1 other source trial
-13% (n=13) @ 102.86wk
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
Dropout rate
0%Part A: Evolocumabh
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
show 4 more results
—Part A: OL Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: DB Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
0%Part B: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
3.3%
NCT03403374 · Phase 4 · registry result, not featured evidence
8.1%Part 1 - Inclisirani
NCT03851705 · Phase 3
show 7 more results
—Part 1: Inclisiran
NCT03851705 · Phase 3
—Part 2 - Inclisiran-Inclisiran
NCT03851705 · Phase 3
—Part 2: Inclisiran
NCT03851705 · Phase 3
—Part 1 - Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
0%Part 1- Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 2 - Inclisiran (Total)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
55.6%
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
Discontinued due to AEs
—Part A: Evolocumabh
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
show 4 more results
—Part A: OL Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: DB Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—
NCT03403374 · Phase 4 · registry result, not featured evidence
—Part 1 - Inclisirani
NCT03851705 · Phase 3
show 7 more results
—Part 1: Inclisiran
NCT03851705 · Phase 3
—Part 2 - Inclisiran-Inclisiran
NCT03851705 · Phase 3
—Part 2: Inclisiran
NCT03851705 · Phase 3
—Part 1 - Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 1- Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 2 - Inclisiran (Total)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
Serious AEs
—Part A: Evolocumabh
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
show 4 more results
0%Part A: OL Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
0%Part B: DB Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
6.7%
NCT03403374 · Phase 4 · registry result, not featured evidence
—Part 1 - Inclisirani
NCT03851705 · Phase 3
show 7 more results
5.4%Part 1: Inclisiran
NCT03851705 · Phase 3
—Part 2 - Inclisiran-Inclisiran
NCT03851705 · Phase 3
20.8%Part 2: Inclisiran
NCT03851705 · Phase 3
0%Part 1 - Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
—Part 1- Inclisiran
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
0%Part 2 - Inclisiran (Total)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
25%
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
Most frequent reported AEs
h
bronchitis 12.5% (placebo 0%)
dyspepsia 12.5% (placebo 0%)
pain 12.5% (placebo 0%)
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
show 2 more results
influenza 9.1% (placebo 0%)
upper respiratory tract infection 9.1% (placebo 6.3%)
gastroenteritis 6.1% (placebo 0%)
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
angina pectoris 3.3%
arthralgia 3.3%
arthritis 3.3%
NCT03403374 · Phase 4 · registry result, not featured evidence
i
diarrhoea 5.4% (placebo 0%)
pyrexia 5.4% (placebo 0%)
respiratory tract infection viral 5.4% (placebo 10.5%)
NCT03851705 · Phase 3
show 4 more results
corona virus infection 7.5% (placebo 0%)
international normalised ratio increased 5.7% (placebo 0%)
activated partial thromboplastin time prolonged 3.8% (placebo 0%)
NCT03851705 · Phase 3
covid-19 44.4% (placebo 25%)
abdominal pain upper 22.2% (placebo 0%)
injection site reaction 22.2% (placebo 0%)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
headache 15.4% (placebo 0%)
influenza 15.4% (placebo 0%)
abdominal pain upper 7.7% (placebo 0%)
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
abdominal pain upper 25%
acne 25%
angina unstable 25%
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2/3 versus Phase 3.
  3. cPopulation context differs: baseline_threshold differs (ldl_c>=130 versus ldl_c>130).
  4. dOne study enrolled healthy volunteers and the other enrolled patients.
  5. ePopulation comparability has not been reviewed for both studies.
  6. fTreatment context has not been resolved for both arms.
  7. gAssessment timepoints differ: 12 weeks versus 102.86 weeks.
  8. hPopulation comparability has not been reviewed for 1 of these studies.
  9. iPopulation comparability has not been reviewed for 5 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Inclisiran

Total Cholesterol -5.9% (n=37) vs 2% (n=19) placebo @ 12.86wk
percent change · % of baseline
NCT03851705 · Phase 3
show 3 more results
1.2% (n=37) vs -1.5% (n=19) placebo @ 21.43wk
NCT03851705 · Phase 3
-4.9% (n=37) vs -1.4% (n=19) placebo @ 25.71wk
NCT03851705 · Phase 3
0.71% (n=37) vs 1.51% (n=19) placebo @ 21.43wk
NCT03851705 · Phase 3
Total Cholesterol Change mg/dL -15.1 vs 3.9 placebo mg/dL @ 12.86wk
absolute change · mg/dL
NCT03851705 · Phase 3
show 2 more results
0.6 vs -10.5 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3
-12.6 vs -6.8 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3
Total Cholesterol -4.8% (n=34) @ 38.57wk
percent change · % of baseline
No placebo or comparator arm
NCT03851705 · Phase 3
show 8 more results
-1% (n=34) @ 47.14wk
NCT03851705 · Phase 3
-2.2% (n=34) @ 64.29wk
NCT03851705 · Phase 3
2.8% (n=34) @ 72.86wk
NCT03851705 · Phase 3
-4.8% (n=34) @ 90wk
NCT03851705 · Phase 3
-1.9% (n=34) @ 98.57wk
NCT03851705 · Phase 3
-2.9% (n=34) @ 102.86wk
NCT03851705 · Phase 3
-13.9% (n=4) @ 12.86wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
-19.8% (n=4) @ 25.71wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
Total Cholesterol Change mg/dL -13.3 mg/dL @ 38.57wk
absolute change · mg/dL
No placebo or comparator arm
NCT03851705 · Phase 3
show 8 more results
-13 mg/dL @ 47.14wk
NCT03851705 · Phase 3
-14.4 mg/dL @ 64.29wk
NCT03851705 · Phase 3
0.1 mg/dL @ 72.86wk
NCT03851705 · Phase 3
-14.9 mg/dL @ 90wk
NCT03851705 · Phase 3
-6.9 mg/dL @ 98.57wk
NCT03851705 · Phase 3
-8.5 mg/dL @ 102.86wk
NCT03851705 · Phase 3
-77.8 mg/dL @ 12.86wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
-118 mg/dL @ 25.71wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
Apo B Change mg/dL -9.4 vs 10 placebo mg/dL @ 12.86wk
absolute change · mg/dL
NCT03851705 · Phase 3
show 2 more results
-1.4 vs 3.3 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3
-7.4 vs 8.4 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3
Apo B Change mg/dL -1.9 mg/dL @ 38.57wk
absolute change · mg/dL
No placebo or comparator arm
NCT03851705 · Phase 3
show 8 more results
-7.3 mg/dL @ 47.14wk
NCT03851705 · Phase 3
-6.9 mg/dL @ 64.29wk
NCT03851705 · Phase 3
1.1 mg/dL @ 72.86wk
NCT03851705 · Phase 3
-10.1 mg/dL @ 90wk
NCT03851705 · Phase 3
-10.3 mg/dL @ 98.57wk
NCT03851705 · Phase 3
-13 mg/dL @ 102.86wk
NCT03851705 · Phase 3
-95.3 mg/dL @ 12.86wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
-86.3 mg/dL @ 25.71wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
Non-HDL-C -7.2% (n=37) vs 2.9% (n=19) placebo @ 12.86wk
percent change · % of baseline
NCT03851705 · Phase 3
show 6 more results
1.3% (n=37) vs -1.7% (n=19) placebo @ 21.43wk
NCT03851705 · Phase 3
-6.2% (n=37) vs -1.1% (n=19) placebo @ 25.71wk
NCT03851705 · Phase 3
0.37% (n=37) vs 2.46% (n=19) placebo @ 21.43wk
NCT03851705 · Phase 3
-24% (n=9) vs 19% (n=4) placebo @ 21.43wk
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
-23.3% (n=9) vs 9.4% (n=4) placebo @ 47.14wk
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
-20.1% (n=9) vs 7.1% (n=4) placebo @ 51.43wk
NCT04659863 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 3
Non-HDL-C Change mg/dL -15.3 vs 3.8 placebo mg/dL @ 12.86wk
absolute change · mg/dL
NCT03851705 · Phase 3
show 2 more results
0.6 vs -11.6 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3
-12.7 vs -5.7 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3
Non-HDL-C Change mg/dL -17.1 mg/dL @ 38.57wk
absolute change · mg/dL
No placebo or comparator arm
NCT03851705 · Phase 3
show 8 more results
-13.9 mg/dL @ 47.14wk
NCT03851705 · Phase 3
-15.8 mg/dL @ 64.29wk
NCT03851705 · Phase 3
-2.4 mg/dL @ 72.86wk
NCT03851705 · Phase 3
-14.7 mg/dL @ 90wk
NCT03851705 · Phase 3
-7.8 mg/dL @ 98.57wk
NCT03851705 · Phase 3
-9.3 mg/dL @ 102.86wk
NCT03851705 · Phase 3
-71.8 mg/dL @ 12.86wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
-108.5 mg/dL @ 25.71wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
HDL-C 1.4% (n=37) vs -1.1% (n=19) placebo @ 12.86wk
percent change · % of baseline
NCT03851705 · Phase 3
show 2 more results
3.6% (n=37) vs 2.3% (n=19) placebo @ 21.43wk
NCT03851705 · Phase 3
1.5% (n=37) vs -1.9% (n=19) placebo @ 25.71wk
NCT03851705 · Phase 3
HDL-C 4.3% (n=34) @ 47.14wk
percent change · % of baseline
No placebo or comparator arm
NCT03851705 · Phase 3
show 7 more results
4.8% (n=34) @ 64.29wk
NCT03851705 · Phase 3
7.9% (n=34) @ 72.86wk
NCT03851705 · Phase 3
0.5% (n=34) @ 90wk
NCT03851705 · Phase 3
4.5% (n=34) @ 98.57wk
NCT03851705 · Phase 3
4.1% (n=34) @ 102.86wk
NCT03851705 · Phase 3
-12.1% (n=4) @ 12.86wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
-19.8% (n=4) @ 25.71wk
NCT02963311 · Phase 2 · registry result, not featured evidence · background therapy
HDL-C Change mg/dL 0.2 vs 0 placebo mg/dL @ 12.86wk
absolute change · mg/dL
NCT03851705 · Phase 3
show 2 more results
0 vs 1 placebo mg/dL @ 21.43wk
NCT03851705 · Phase 3
0 vs -1.2 placebo mg/dL @ 25.71wk
NCT03851705 · Phase 3

+ 9 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Evolocumab's landscape · Inclisiran's landscape